[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EP2383350B1 - Verfahren zur diagnose oder behandlung von prostatakrebs mittels erg-gen, alleine oder in kombination mit anderen ober- oder unterexprimierten genen bei prostatakrebs - Google Patents

Verfahren zur diagnose oder behandlung von prostatakrebs mittels erg-gen, alleine oder in kombination mit anderen ober- oder unterexprimierten genen bei prostatakrebs Download PDF

Info

Publication number
EP2383350B1
EP2383350B1 EP11172817.6A EP11172817A EP2383350B1 EP 2383350 B1 EP2383350 B1 EP 2383350B1 EP 11172817 A EP11172817 A EP 11172817A EP 2383350 B1 EP2383350 B1 EP 2383350B1
Authority
EP
European Patent Office
Prior art keywords
gene
erg
expression
seq
prostate cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP11172817.6A
Other languages
English (en)
French (fr)
Other versions
EP2383350A1 (de
Inventor
Gyorgy Petrovics
Shiv Srivastava
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Original Assignee
Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henry M Jackson Foundation for Advancedment of Military Medicine Inc filed Critical Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Publication of EP2383350A1 publication Critical patent/EP2383350A1/de
Application granted granted Critical
Publication of EP2383350B1 publication Critical patent/EP2383350B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Definitions

  • the present invention relates to oncogenes, tumor suppressor genes, as well as other genes, and their expression products, involved in prostate cancer, as well as derivatives and analogs thereof.
  • the invention further relates to therapeutic compositions and methods of detecting, diagnosing, and treating cancer, including prostate and other related cancers.
  • Prostate cancer is the most common malignancy in American men and second leading cause of cancer mortality ( Landis et al. (1999) Cancer J. Clin., 49:8-31 ; Jemal et al. (2004) Cancer J Clin 54:8-29 ).
  • the molecular determinants in the development and progression of this disease are poorly understood.
  • there have been intensive investigations of molecular genetics of the CaP To date, however, oncogene, tumor suppressor gene, or other gene alterations common to most CaPs have not been found. Alterations of tumor suppressors such as p53, PTEN and p27, or oncogenes such as BCL2, HER2 and C-MYC associate with only small subsets of primary CaP, with more frequent association observed in advanced CaP.
  • These methods and kits can be used to detect (either qualitatively or quantitatively) nucleic acids or proteins that serve as cancer markers.
  • the expression of the prostate cancer-cell-specific gene ERG when detected in a biological sample from a subject, either alone or in combination with other cancer markers, including the expression of other prostate cancer-cell-specific genes, can be used to indicate the presence of prostate cancer in the subject or a higher predisposition of the subject to develop prostate cancer.
  • Detecting ERG expression alone or in combination with the expression of any gene identified in Tables 1-6, can thus be used to diagnose or prognose cancer, particularly prostate cancer.
  • the present invention provides a method of diagnosing prostate cancer in a subject or a higher predisposition of the subject to developing prostate cancer, comprising: (a) measuring the expression level of an ERG gene in a biological sample from the subject, wherein the ERG gene comprises both ERG1 (SEQ ID NO: 1) and ERG2 (SEQ ID NO: 2); (b) correlating the expression level of the ERG gene with the presence of prostate cancer or a higher predisposition of the subject to developing prostate cancer, wherein increased expression of the ERG gene in the biological sample as compared to the expression of the ERG gene in a control sample or a standardized value correlates with the presence of prostate cancer or a higher predisposition of the subject to developing prostate cancer.
  • the invention also provides use of kits in methods according to the invention in accordance with the claims.
  • the expression levels can be quantified such that increased or decreased expression levels relative to a control sample or other standardized value or numerical range indicate the presence of prostate cancer or a higher predisposition to develop prostate cancer.
  • the increased or decreased expression levels in the methods of the invention may be measured relative to the expression level of the prostate cancer cell-specific gene or polypeptide in normal, matched tissue, such as benign prostate epithelial cells from the same subject.
  • the expression level of a gene or polypeptide may be measured relative to the expression of the gene or polypeptide in other noncancerous samples from the subject or in samples obtained from a different subject without cancer.
  • Expression of a gene may also be normalized by comparing it to the expression of other cancer-specific markers.
  • a prostate-cell specific marker such as PSA, can be used as a control to compare and/or normalize expression levels of other genes, such as ERG, LTF, DD3, and/or AMACR.
  • the method of diagnosing or prognosing prostate cancer comprises measuring the expression levels of the ERG, DD3 and/or AMACR gene and diagnosing or prognosing prostate cancer, where an increased expression level of the ERG, DD3, and/or AMACR gene of at least two times as compared to the control sample indicates the presence of prostate cancer or a higher predisposition in the subject to develop prostate cancer.
  • an increased expression level of the ERG, DD3, and/or AMACR gene of at least two times as compared to the control sample indicates the presence of prostate cancer or a higher predisposition in the subject to develop prostate cancer.
  • prostate cancer cell-specific genes e.g., mRNA or polypeptide expression
  • any other known detection methods including, without limitation, immunohistochemistry, Southern blotting, Northern blotting, Western blotting, ELISA, and nucleic acid amplification procedures, including but not limited to PCR, transcription-mediated amplification (TMA), nucleic acid sequence-based amplification (NASBA), self-sustained sequence replication (3SR), ligase chain reaction (LCR), strand displacement amplification (SDA), and Loop-Mediated Isothermal Amplification (LAMP).
  • TMA transcription-mediated amplification
  • NASBA nucleic acid sequence-based amplification
  • 3SR self-sustained sequence replication
  • LCR ligase chain reaction
  • SDA strand displacement amplification
  • LAMP Loop-Mediated Isothermal Amplification
  • ERG is detected in combination with other prostate cancer cell-specific genes (identified in Tables 1-6), including AMACR and/or LTF, to obtain expression profiles from biological samples.
  • the expression profiles of these prostate cancer-cell-specific genes are useful for detecing cancer, particularly prostate cancer.
  • ERG can also be detected in combination with DD3, with or without other prostate cancer cell-specific genes, such as AMACR and/or LTF, to obtain expression profiles from biological samples. These expression profiles are also useful for detecting cancer, particularly prostate cancer.
  • Increased levels of ERG, AMACR, and/or DD3 in a biological sample indicate the presence of prostate cancer or a higher predisposition in the subject to develop prostate cancer.
  • Decreased levels of LTF in a biological sample indicate the presence of prostate cancer or a higher predisposition in the subject to develop prostate cancer.
  • a method of determining a gene expression pattern in a biological sample where the pattern can be used to indicate or predict the pathologic stage of cancer, particularly prostate cancer.
  • the gene expression pattern can be used to indicate or predict a moderate risk prostate cancer or a high risk prostate cancer or to predict whether the prostate cancer is progressing or regressing or in remission.
  • the gene expression pattern can also be used as a prognostic indictor of disease-free survival following radical prostatectomy.
  • gene expression patterns are derived from the expression level of the ERG gene, alone or in combination with other prostate cancer-cell-specific genes (identified in Tables 1-6), including AMACR and LTF, or DD3.
  • the present invention is based in part on the identification of gene expression signatures that correlate with a high risk of CaP progression. Over expression or under expression of specific genes are predictive of tumor progression.
  • the invention provides genes, such as the ERG gene, and analogs of specific genes that can be used alone or in combination with DD3 or other CaP-cell-specific genes, such as AMACR or LTF, to function as diagnostic and prognostic targets for cancer, particularly prostate tumors.
  • the invention further provides genes, such as the ERG gene, and analogs of specific genes that can be used alone or in combination as therapeutic targets for cancer, in particular prostate tumors.
  • kits comprised of an anti-CaP-cell-specific gene antibody, for example, an anti-ERG gene antibody, which is optionally, detectably labeled.
  • a kit is also provided that comprises nucleic acid primer sequences and/or a nucleic acid probe capable of hybridizing under defined conditions (preferably high stringency hybridization conditions, e.g., hybridization for 48 hours at 65°C in 6X SSC followed by a wash in 0.1X SSX at 50°C for 45 minutes) to an ERG nucleic acid.
  • kits may also contain an anti-DD3 gene antibody or a second anti-CaP-cell-specific gene antibody, such as an anti-AMACR or anti-LTF gene antibody, or a second set of nucleic acid primer sequences and/or a nucleic acid probe capable of hybridizing under defined conditions to the DD3 gene or another CaP-cell-specific gene, such as the AMACR or LTF gene.
  • an anti-DD3 gene antibody or a second anti-CaP-cell-specific gene antibody such as an anti-AMACR or anti-LTF gene antibody
  • a second set of nucleic acid primer sequences and/or a nucleic acid probe capable of hybridizing under defined conditions to the DD3 gene or another CaP-cell-specific gene, such as the AMACR or LTF gene.
  • the disclosed CaP-cell-specific genes such as ERG, can be used alone or in combination as biomarkers of cancer, and in particular, prostate cancers and other related diseases, as targets for therapeutic intervention, or as gene therapy agents.
  • disorders of hyperproliferation e.g., cancer, benign tumors
  • compounds that modulate expression of the specific genes are also described.
  • Methods of screening cancer cells, and in particular, prostate cancer cells, for specific gene expression signatures, including ERG gene expression signatures, alone or in combination with DD3 gene expression signatures or other CaP-cell-specific gene expression signatures, such as AMACR or LTF, are provided.
  • CaP-cell-specific gene refers to a gene identified in Tables 1-6.
  • the definition further encompasses CaP-cell-specific gene analogs, e.g., orthologues and homologues, and functionally equivalent fragments of CaP-cell-specific genes or their analogs, the expression of which is either upregulated or downregulated in prostate cancer cells.
  • CaP-cell-specific gene expression signature refers to the pattern of upregulation or downregulation of product expression as measured by the Affymetrix GeneChip assay described in Example 1, the QRT-PCR assay described in Example 2, or any other quantitative expression assay known in the art.
  • ERG refers to the ERG gene or ERG cDNA or mRNA described herein, and includes ERG isoforms, such as ERG1 and ERG2.
  • the cDNA sequence of the ERG1 gene is published in GenBank under the accession number M21535.
  • the cDNA sequence of the ERG2 gene is published in GenBank under the accession number M17254.
  • AMACR refers to the AMACR gene or AMACR cDNA or mRNA described herein, and includes AMACR isoforms.
  • the cDNA sequence of the AMACR gene is published in GenBank under the accession number NM_014324.
  • DD3 refers to the DD3 gene or DD3 cDNA or mRNA described herein, and includes DD3 isoforms.
  • the cDNA sequence of the DD3 gene is published in GenBank under the accession number AF 103907 and is also disclosed in WO 98/45420 (1998 ).
  • PCA3 prostate cancer antigen 3
  • LTF refers to the LTF gene or LTF cDNA or mRNA described herein and includes LTF isoforms.
  • the cDNA sequence of the LTF gene is published in GenBank under the accession number NM_002343.
  • polypeptide is used interchangeably with the terms “peptide” and “protein” and refers to any chain of amino acids, regardless of length or posttranslational modification (e.g., glycosylation or phosphorylation), or source (e.g., species).
  • substantially identical means that a relevant sequence is at least 70%, 75%, 80%, 85%, 90%, 95%, 97, 98, or 99% identical to a given sequence.
  • sequences may be allelic variants, sequences derived from various species, or they may be derived from the given sequence by truncation, deletion, amino acid substitution or addition.
  • the length of comparison sequences will generally be at least 20, 30, 50, 100 or more amino acids.
  • the length of comparison sequences will generally be at least 50, 100, 150, 300, or more nucleotides.
  • Percent identity between two sequences is determined by standard alignment algorithms such as, for example, Basic Local Alignment Tool (BLAST) described in Altschul et al. (1990) J. Mol. Biol., 215:403-410 , the algorithm of Needleman et al. (1970) J. Mol. Biol., 48:444-453 , or the algorithm of Meyers et al. (1988) Comput. Appl. Biosci., 4:11-17 .
  • BLAST Basic Local Alignment Tool
  • binding means that two molecules form a complex that is relatively stable under physiologic conditions.
  • the term is also applicable where, e.g., an antigen-binding domain is specific for a particular epitope, which is carried by a number of antigens, in which case the specific binding member carrying the antigen-binding domain will be able to bind to the various antigens carrying the epitope.
  • Specific binding is characterized by a high affinity and a low to moderate capacity. Nonspecific binding usually has a low affinity with a moderate to high capacity.
  • the binding is considered specific when the affinity constant K a is higher than 10 6 M -1 , more preferably higher than 10 7 M -1 , and most preferably 10 8 M -1 .
  • non-specific binding can be reduced without substantially affecting specific binding by varying the binding conditions.
  • conditions are known in the art, and a skilled artisan using routine techniques can select appropriate conditions.
  • the conditions are usually defined in terms of concentration of antibodies, ionic strength of the solution, temperature, time allowed for binding, concentration of non-related molecules (e.g., serum albumin, milk casein), etc.
  • detectably labeled refers to any means for marking and identifying the presence of a molecule, e.g., an oligonucleotide probe or primer, a gene or fragment thereof, or a cDNA molecule.
  • Methods for labeling a molecule include, without limitation, radioactive labeling (e.g., with an isotope such as 32 P, 35 S, or 125 I) and nonradioactive labeling (e.g., fluorescent and chemiluminescent labeling).
  • radioactive labeling e.g., with an isotope such as 32 P, 35 S, or 125 I
  • nonradioactive labeling e.g., fluorescent and chemiluminescent labeling
  • modulatory compound is used interchangeably with the term “therapeutic” as used herein means any compound capable of “modulating” either CaP-cell-specific gene expression at the transcriptional, translational, or post-translational levels or modulating the biological activity of a CaP-cell-specific polypeptide.
  • modulate and its cognates refer to the capability of a compound acting as either an agonist or an antagonist of a certain reaction or activity.
  • modulate therefore, encompasses the terms “activate” and "inhibit.”
  • activate refers to an increase in the expression of the CaP-cell-specific gene or activity of a CaP-cell-specific polypeptide in the presence of a modulatory compound, relative to the activity of the gene or the polypeptide in the absence of the same compound.
  • the increase in the expression level or the activity is preferably at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or higher.
  • the term "inhibit” refers to a decrease in the expression of the CaP-cell-specific gene or activity of a CaP-cell-specific polypeptide in the presence of a modulatory compound, relative to the activity of the gene or the polypeptide in the absence of the same compound.
  • the decrease in the expression level or the activity is preferably at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or higher.
  • the expression level of the CaP-cell-specific gene or activity of a CaP-cell-specific polypeptide can be measured as described herein or by techniques generally known in the art.
  • treatment is used interchangeably herein with the term “therapeutic method” and refers to both therapeutic treatment and prophylactic/preventative measures.
  • Those in need of treatment may include individuals already having a particular medical disorder as well as those who may ultimately acquire the disorder.
  • isolated refers to a molecule that is substantially free of its natural environment. Any amount of that molecule elevated over the naturally occurring levels due to any manipulation, e.g., over expression, partial purification, etc., is encompassed with the definition. With regard to partially purified compositions only, the term refers to an isolated compound that is at least 50-70%, 70-90%, 90-95% (w/w), or more pure.
  • an effective dose refers to that amount of the compound that results in amelioration of symptoms in a patient or a desired biological outcome, e.g., inhibition of cell proliferation.
  • the effective amount can be determined as described in the subsequent sections.
  • polynucleotide refers to deoxyribonucleic acid (DNA), and, where appropriate, ribonucleic acid (RNA).
  • RNA ribonucleic acid
  • polynucleotides include, but are not limited to, plasmid DNA or fragments thereof, viral DNA or RNA, anti-sense RNA, etc.
  • plasmid DNA refers to double stranded DNA that is circular.
  • hybridization under defined conditions or “hybridizing under defined conditions,” is intended to describe conditions for hybridization and washes under which nucleotide sequences that are significantly identical or homologous to each other remain bound to each other.
  • the conditions are such that sequences, which are at least about 6 and more preferably at least about 20, 50, 100, 150, 300, or more nucleotides long and at least about 70%, more preferably at least about 80%, even more preferably at least about 85-90% identical, remain bound to each other.
  • the percent identity can be determined as described in Altschul et al. (1997) Nucleic Acids Res., 25: 3389-3402 .
  • Filters containing DNA are pretreated for 6 hours at 40°C in a solution containing 35% formamide, 5x SSC, 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.1% PVP, 0.1% Ficoll, 1% BSA, and 500 ⁇ g/ml denatured salmon sperm DNA.
  • Hybridizations are carried out in the same solution with the following modifications: 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 ⁇ g/ml salmon sperm DNA, 10% (wt/vol) dextran sulfate, and 5-20 x 10 6 cpm 32 P-labeled probe is used.
  • Filters are incubated in hybridization mixture for 18-20 hours at 40°C, and then washed for 1.5 hours at 55°C in a solution containing 2x SSC, 25 mM Tris-HCl (pH 7.4), 5 mM EDTA, and 0.1% SDS. The wash solution is replaced with fresh solution and incubated an additional 1.5 hours at 60°C. Filters are blotted dry and exposed for autoradiography. Other conditions of low stringency well known in the art may be used (e.g., as employed for cross-species hybridizations).
  • a non-limiting example of defined conditions of high stringency is as follows. Prehybridization of filters containing DNA is carried out for 8 hours to overnight at 65°C in buffer composed of 6x SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 ⁇ g/ml denatured salmon sperm DNA. Filters are hybridized for 48 hours at 65°C in the prehybridization mixture containing 100 ⁇ g/ml denatured salmon sperm DNA and 5-20 x 10 6 cpm of 32 P-labeled probe.
  • solid support means a material that is essentially insoluble under the solvent and temperature conditions of the assay method, comprising free chemical groups available for joining an oligonucleotide or nucleic acid.
  • the solid support is covalently coupled to an oligonucleotide designed to directly or indirectly bind a target nucleic acid.
  • the oligonucleotide attached to the solid support is preferably a poly-T sequence.
  • a preferred solid support is a particle, such as a micron- or submicron-sized bead or sphere.
  • solid support materials such as, for example, silica, polyacrylate, polyacrylamide, a metal, polystyrene, latex, nitrocellulose, polypropylene, nylon or combinations thereof. More preferably, the solid support is capable of being attracted to a location by means of a magnetic field, such as a solid support having a magnetite core. Particularly preferred supports are monodisperse magnetic spheres (i.e., uniform size.+-.about 5%).
  • detecting means any of a variety of methods for determining the presence of a nucleic acid, such as, for example, hybridizing a labeled probe to a portion of the nucleic acid.
  • a labeled probe is an oligonucleotide that specifically binds to another sequence and contains a detectable group which may be, for example, a fluorescent moiety, a chemiluminescent moiety (such as an acridinium ester (AE) moiety that can be detected chemiluminescently under appropriate conditions (as described in U.S. Pat. No. 5,283,174 )), a radioisotope, biotin, avidin, enzyme, enzyme substrate, or other reactive group.
  • AE acridinium ester
  • detection techniques include, for example, gel filtration, gel electrophoresis and visualization of the amplicons, and High Performance Liquid Chromatography (HPLC).
  • detecting or “detection” includes either qualitative or quantitative detection.
  • primer means an oligonucleotide capable of binding to a region of a target nucleic acid or its complement and promoting nucleic acid amplification of the target nucleic acid.
  • a primer will have a free 3' end that can be extended by a nucleic acid polymerase.
  • Primers also generally include a base sequence capable of hybridizing via complementary base interactions either directly with at least one strand of the target nucleic acid or with a strand that is complementary to the target sequence.
  • a primer may comprise target-specific sequences and optionally other sequences that are non-complementary to the target sequence. These non-complementary sequences may comprise a promoter sequence or a restriction endonuclease recognition site.
  • the present invention is based in part on the identification and validation of consistent CaP epithelial cell specific gene expression signatures.
  • These gene expression signatures define patients with CaP who are at risk to develop advanced disease by identifying genes and pathways in prostate epithelial cells that differentiate between aggressive and non-aggressive courses of cancer development.
  • Two patient groups were selected, a high risk (HR) group having, for example, PSA recurrence, Gleason score 8-9, T3c stage, seminal vesicle invasion, poor tumor differentiation, and a moderate risk (MR) group having, for example, no PSA recurrence, Gleason score 6-7, T2a-T3b stage, no seminal vesicle invasion, well or moderate tumor differentiation.
  • HR high risk
  • MR moderate risk
  • the two patient groups were matched for known risk factors: age, race, and family history of CaP.
  • LCM derived epithelial cells from tumor and normal prostate of the two patient groups were compared by GeneChip analyses, as described in the following Example 1. Results were validated using quantitative reverse transcriptase PCR (QRT-PCR), as described in the following Example 2.
  • QRT-PCR quantitative reverse transcriptase PCR
  • ERG ETS related gene
  • Nucleotides 195-1286 of SEQ ID NO:1 represent the coding sequence of SEQ ID NO:1.
  • ERG2 coding sequence is publicly available through GenBank under the accession number M17254, as follows (with start and stop codons underlined):
  • Nucleotides 257-1645 of SEQ ID NO:2 represent the coding sequence of SEQ ID NO:2.
  • AMACR a recently identified CaP tissue marker ( Rubin et al, JAMA (2002) 287:1662-1670 ; Luo et al., Cancer Res (2002) 62: 2220-2226 ), and of GSTP1, a gene known to have decreased expression in CaP ( Nelson et al., Ann N Y Acad Sci (2001) 952: 135-144 ), was also determined ( Figure 1B and 1C ). Robust over expression in CaP cells of 95% of the patients, similarly to ERG, was observed for AMACR, while the GSTP1 expression was significantly decreased in the tumor cells of each CaP patient, confirming the high quality of the tumor and benign LCM specimens and the reliability of the QRT-PCR.
  • ERG and ETS are proto-oncogenes with mitogenic and transforming activity.
  • Sharrocks, AD Nat Rev Mol Cell Biol (2001) 2(11):827-37 ; Seth et al., Proc Natl Acad Sci USA (1989) 86:7833-7837 ).
  • Deregulation or chromosomal reorganization of ERG is linked to Ewing sarcoma, myeloid leukemia and cervical carcinoma.
  • ETS2 has been implicated in CaP, but it is over expressed only in a small proportion of CaP specimens.
  • ERG over expression without amplification of DNA copy number was recently reported in acute myeloid leukemia. ( Balduc et al., Proc. Natl. Acad. Sci. USA (2004) 101:3915-20 ). Gavrilov et al., Eur J Cancer (2001) 37:1033-40 examined the expression of various transcription factors, including several proteins from the ETS family, in a very limited number of high-grade prostate cancer samples. Antibodies against the ETS family proteins, Elf-1 and Fli-1, caused intense staining of most of the high-grade prostate cancer samples.
  • ERG protein while being detected in the noncancerous endothelial cells (microvessels in the stroma) of most samples tested, was detected in only a minority of the high-grade prostate cancers.
  • ETS family proteins have a variety of expression patterns in human tissues. ( Oikawa et al., Gene (2003) 303:11-34 ). ERG is expressed in endothelial tissues, hematopoietic cells, kidney, and in the urogenital tract. ERG proteins are nuclear transcription factors that form homodimers, as well as heterodimers with several other members of the ETS family of transcription factors. ( Carrere et al., Oncogene (1998) 16(25): 3261-68 ).
  • ERG ERG and estrogen receptor (ER-alpha) may be relevant in urogenital tissues, where both transcription factors are expressed.
  • ER-alpha estrogen receptor
  • the present invention is based in part upon the surprising discovery that ERG is over expressed in the majority of CaP specimens analyzed, indicating that this oncogene plays a role in prostate tumorigenesis, most likely by modulating transcription of target genes favoring tumorigenesis in prostate epithelium.
  • the present invention is further based in part upon the over expression of the AMACR gene in prostate cancer epithelium.
  • the cDNA sequence of the AMACR is publicly available through GenBank under the accession numbers NM_014324 and AF047020.
  • the sequence (with start and stop codons underlined) corresponding to accession number NM_014324 is as follows:
  • Nucleotides 83-1231 of SEQ ID NO:3 represent the coding sequence of AMACR.
  • the present invention is further based in part upon the over expression of the DD3 gene in prostate cancer epithelium.
  • the cDNA sequence of the DD3 gene is publicly available through GenBank under the accession number AF103907.
  • the sequence corresponding to accession number AF103907 is as follows:
  • the DD3 gene appears to represent a non-coding nucleic acid. Therefore, no start and stop codons have been indicated.
  • the present invention is further based in part upon the under expression of the LTF gene in prostate cancer epithelium.
  • the cDNA sequence of the lactotransferrin (LTF) gene is publicly available through GenBank under the accession number NM_002343.
  • the sequence (with start and stop codons underlined) corresponding to accession number NM_002343 is as follows:
  • Nucleotides 39-2171 of SEQ ID NO:5 represent the coding sequence of LTF.
  • LTF is a non-heme iron binding glycoprotein and a member of the transferring gene family. Bowman et al., Adv. Genet. 25:1-38 (1988 ); Park et al., Proc. Natl. Acad. Sci. U.S.A., 82:3149-53 (1985 ). The concentration of LTF in human prostate is hormone dependent and its expression is regulated by estrogen. van Sande et al., Urol. Res., 9(5):241-44 (1981 ); Teng et al., Biochem. CellBiol., 80:7-16 (2002 ); Teng et al., Mol. Human Reproduction., 8, (1):58-67 (2002 ). LTF has also been implicated in certain cancers.
  • bovine LTF inhibits colon, esophagus, lung, and bladder carcinomas in rats.
  • Tsuda et al. Biochem. Cell Biol., 80:131-136 (2002 ); Tsuda et al., Biofactors., 12(1-4):83-8 (2000 ); Tsuda et al., Biofactors., 12(1-4):83-8 (2000 ); Tsuda et al., Mutat Res., 462(2-3):227-33 (2000 ).
  • van Sande et al., Urol. Res. 9:241-244 (1981 ) examined lactoferrin protein levels in human benign prostatic hypertrophy samples.
  • the present invention comprises a method of CaP diagnosis comprising screening biological samples for CaP-cell-specific gene expression signatures.
  • the invention comprises screening for at least one of the CaP-cell-specific genes listed in Tables 1-6, particularly the ERG gene, the AMACR gene, the LTF gene or a combination of the ERG gene and the AMACR genes in accordance with the claims.
  • the invention also comprises methods of diagnosing CaP comprising screening biological samples for expression of the ERG and DD3 genes, or a combination of the ERG, DD3, and AMACR genes in accordance with the claims.
  • the present invention comprises a method of CaP diagnosis comprising screening biological samples for CaP-cell-specific gene expression signatures using methods known in the art, including, for example, immunohistochemistry, ELISA, in situ RNA hybridization, and any oligonucleitde amplification procedure known or later developed, including PCR (including QRT-PCR), transcription-mediated amplification (TMA), nucleic acid sequence-based amplification (NASBA), self-sustained sequence replication (3SR), ligase chain reaction (LCR), strand displacement amplification (SDA), and Loop-Mediated Isothermal Amplification (LAMP).
  • PCR including QRT-PCR
  • TMA transcription-mediated amplification
  • NASBA nucleic acid sequence-based amplification
  • 3SR self-sustained sequence replication
  • LCR ligase chain reaction
  • SDA strand displacement amplification
  • LAMP Loop-Mediated Isothermal Amplification
  • the invention comprises generating antibodies to CaP-cell-specific genes, including ERG, AMACR, LTF, and DD3 for use in a immunohistochemistry assay. Other known diagnostic assays may be used to detect gene expression.
  • the present invention comprises a method of diagnosing CaP in accordance with the claims comprising screening biological samples for expression of the ERG and AMACR genes, the ERG and DD3 genes, or the ERG, AMACR, and DD3 genes, or the LTF gene using methods known in the art, including, for example, immunohistochemistry, ELISA, in situ hybridization, PCR (including QRT-PCR), transcription-mediated amplification (TMA), nucleic acid sequence-based amplification (NASBA), self-sustained sequence replication (3SR), ligase chain reaction (LCR), strand displacement amplification (SDA), and Loop-Mediated Isothermal Amplification (LAMP).
  • TMA transcription-mediated amplification
  • NASBA nucleic acid sequence-based amplification
  • SDA strand displacement amplification
  • LAMP Loop-Mediated Isothermal Amplification
  • ERG, LTF, or AMACR polypeptides may be used as immunogens in order to generate antibodies that specifically bind such immunogens.
  • Such antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, single chain and Fab fragments.
  • antibodies to a human ERG, LTF or AMACR protein are produced. Antibodies can then be used in standard diagnostic assays to detect the protein produced by the desired gene.
  • polyclonal antibodies to an ERG, LTF, or AMACR protein or derivative or analog may be used for the production of polyclonal antibodies to an ERG, LTF, or AMACR protein or derivative or analog.
  • rabbit polyclonal antibodies to an epitope of a ERG, LTF, or AMACR protein can be obtained.
  • various host animals can be immunized by injection with the native ERG, LTF, or AMACR protein, or a synthetic version, or derivative (e.g., fragment) thereof, including but not limited to rabbits, mice, rats, etc.
  • adjuvants may be used to increase the immunological response, depending on the host species, and including, but not limited to, Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and corynebacterium parvum.
  • Freund's complete and incomplete
  • mineral gels such as aluminum hydroxide
  • surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol
  • BCG Bacille Calmette-Guerin
  • corynebacterium parvum corynebacterium parvum
  • any technique which provides for the production of antibody molecules by continuous cell lines in culture may be used.
  • the hybridoma technique originally developed by Kohler et al (1975) Nature, 256:495-497 , as well as the trioma technique, the human B-cell hybridoma technique ( Kozbor et al. (1983) Immunology Today, 4:72 ), and the EBV-hybridoma technique to produce human monoclonal antibodies Cole et al. (1985) Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96 ).
  • Human antibodies may be used and can be obtained by using human hybridomas ( Cote et al. (1983) Proc. Natl. Acad. Sci. U.S.A., 80:2026-2030 ) or by transforming human B cells with EBV virus in vitro ( Cole et al. (1985) Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, pp. 77-96 ). Techniques developed for the production of chimeric antibodies ( Morrison et al. (1984) Proc. Natl. Acad. Sci. U.S.A., 81:6851-6855 ; Neuberger et al. (1984) Nature, 312:604-608 ; Takeda et al.
  • Antibody fragments which contain the idiotype of the molecule can be generated by known techniques.
  • such fragments include but are not limited to: the F(ab') 2 fragment which can be produced by pepsin digestion of the antibody molecule; the Fab' fragments which can be generated by reducing the disulfide bridges of the F(ab') 2 fragment, the Fab fragments which can be generated by treating the antibody molecule with papain and a reducing agent, and Fv fragments, including single chain Fv (scFv) fragments.
  • screening for the desired antibody can be accomplished by techniques known in the art, e.g., ELISA.
  • ELISA e.g., ELISA
  • the use of the expression profiles resulting from these methods in diagnostic methods including, but not limited to, characterizing the treatment response to any therapy, correlating expression profiles with clinico-pathologic features, distinguishing indolent prostate cancers from those with a more aggressive phenotype (e.g. moderate risk versus high risk), analyzing tumor specimens of patients treated by radical prostate surgery to help define prognosis, screening candidate genes for the development of a polynucleotide array for use as a blood test for improved prostate cancer detection, and identifying further genes that may serve as biomarkers for response to treatment to screen drugs for the treatment of advanced prostate cancer.
  • diagnostic methods including, but not limited to, characterizing the treatment response to any therapy, correlating expression profiles with clinico-pathologic features, distinguishing indolent prostate cancers from those with a more aggressive phenotype (e.g. moderate risk versus high risk), analyzing tumor specimens of patients treated by radical prostate surgery to help define prognosis, screening candidate genes for the development of a polynucleotide array for use
  • the ERG, LTF, DD3, and/or the AMACR nucleic acid sequences described herein can easily be synthesized directly on a support, or pre-synthesized polynucleotide probes may be affixed to a support as described, for example, in U.S. Patent Nos. 5,744,305 , 5,837,832 , and 5,861,242 .
  • Such arrays may be used to detect specific nucleic acid sequences contained in a target cell or sample, as described in U.S. Patent Nos. 5,744,305 , 5,837,832 , and 5,861,242 . More specifically, in the present invention, these arrays may be used in methods for the diagnosis or prognosis of prostate cancer, such as by assessing the expression profiles of genes, in biological samples. In a preferred embodiment, computer models may be developed for the analysis of expression profiles. Moreover, such polynucleotide arrays are useful in methods to screen drugs for the treatment of advanced prostate cancer. In these screening methods, the polynucleotide arrays are used to analyze how drugs affect the expression of the ERG, LTF, AMACR, and/or DD3 genes.
  • therapeutics include but are not limited to: ERG or LTF proteins and analogs and derivatives (including fragments) thereof (e.g., as described herein above); nucleic acids encoding the ERG or LTF proteins, analogs, or derivatives; ERG or LTF antisense nucleic acids, ERG or LTF dominant negative mutants, siRNA against ERG or LTF, ERG or LTF antibodies and ERG or LTF agonists and antagonists.
  • ERG or LTF agonists and antagonists can be identified using the methods disclosed in this application or any standard screening assay to identify agents that modulate ERG or LTF expression or function, particularly in prostate cancer cells.
  • ERG or LTF expression or function can be readily detected, e.g., by obtaining a biological sample from a patient, e.g., a tissue sample (e.g., from biopsy tissue), a blood sample, or a urine sample, and assaying it in vitro for mRNA or protein levels, structure and/or activity of the expressed ERG or LTF mRNA or protein.
  • ERG or LTF protein e.g., Western blot, immunoprecipitation followed by SDS-PAGE, immunocytochemistry, etc.
  • hybridization assays to detect ERG or LTF expression by detecting and/or visualizing ERG or LTF mRNA (e.g., Northern assays, dot blots, in situ hybridization, PCR (including RT-PCR), TMA, NASAB, 3SR, LCR, SDA, LAMP, etc.).
  • ERG function may be inhibited by use of ERG antisense nucleic acids.
  • nucleic acids of at least 10, 15, 100, 200, 500, 1000, 1500, 2000, or 2500 contiguous nucleotides in antisense to any of the ERG nucleotides described herein.
  • the ERG antisense nucleic acid may comprise at least 10, 15, 100, 200, 500, 1000, 1500, 2000, or 2500 contiguous nucleotides in antisense orientation to the ERG nucleotide sequence.
  • an ERG “antisense” nucleic acid refers to a nucleic acid capable of hybridizing under defined conditions to a portion of an ERG nucleic acid by virtue of some sequence complementarity.
  • the antisense nucleic acid may be complementary to a coding and/or noncoding region of an ERG nucleic acid.
  • Such antisense nucleic acids have utility as therapeutics that inhibit ERG function, and can be used in the treatment or prevention of disorders as described herein.
  • the antisense nucleic acids can be oligonucleotides that are double-stranded or single-stranded, RNA or DNA or a modification or derivative thereof, which can be directly administered to a cell, or which can be produced intracellularly by transcription of exogenously, introduced coding sequences.
  • the dominant negative mutants can be produced by expression plasmids containing a nucleic acid encoding a non-functional domain of ERG, such as the DNA binding domain of ERG. These expression plasmids can be introduced into a target cell or tissue and can induce tumor growth inhibition and apoptosis by acting as a dominant negative form against the wild-type ERG transcription factors influencing cell hyperproliferation ( Oikawa, Cancer Sci (2004), 95:626-33 ).
  • RNA interference can be achieved using siRNA against the ERG gene.
  • the siRNA is a short double stranded RNA molecule of about 18-25 nucleotides that comprises a nucleotide sequence complementary to a region of the target gene.
  • the siRNA can be introduced into a target cell or tissue, for example using an expression plasmid, where it interferes with the translation of the ERG gene.
  • RNA interference techniques can be carried out using known methods as described, for example, in published U.S. Patent Applications 20040192626 , 20040181821 , and 20030148519 .
  • Therapeutics which are useful for treatment of a disorder may be selected by testing for biological activity in promoting the survival or differentiation of cells.
  • a therapeutic decreases proliferation of tumor cells.
  • Malignancy or dysproliferative changes such as metaplasias and dysplasias, or hyperproliferative disorders, may be treated or prevented in the prostate.
  • the therapeutics that antagonize ERG activity can also be administered to treat premalignant conditions and to prevent progression to a neoplastic or malignant state, including but not limited to those disorders described herein, such as prostate cancer.
  • nucleic acids comprising a sequence encoding an ERG or LTF protein or functional derivative thereof, are administered to promote ERG or LTF function, by way of gene therapy.
  • nucleic acids comprising an antisense ERG sequence are administered to antagonize ERG expression or function.
  • Gene therapy refers to therapy performed by the administration of a nucleic acid to a subject.
  • the therapeutic comprises an ERG or LTF nucleic acid or antisense ERG nucleic acid that is part of a vector.
  • a nucleic acid has a regulatory sequence, such as a promoter, operably linked to the ERG or LTF coding region or antisense molecule, said promoter being inducible or constitutive, and, optionally, tissue-specific.
  • a nucleic acid molecule is used in which the ERG or LTF coding sequences and any other desired sequences are flanked by regions that promote homologous recombination at a desired site in the genome, thus providing for intrachromosomal expression of the ERG or LTF nucleic acid ( Koller et al. (1989) Proc. Natl. Acad. Sci. U.S.A., 86:8932-8935 ; Zijlstra et al. (1989) Nature, 342:435-438 ).
  • the nucleic acid to be introduced for purposes of gene therapy comprises an inducible promoter operably linked to the desired nucleic acids, such that expression of the nucleic acid is controllable by the appropriate inducer of transcription.
  • Delivery of the nucleic acid into a patient may be either direct, in which case the patient is directly exposed to the nucleic acid or nucleic acid-carrying vector, or indirect, in which case, cells are first transformed with the nucleic acid in vitro, then transplanted into the patient. These two approaches are known, respectively, as in vivo or ex vivo gene therapy.
  • the nucleic acid is directly administered in vivo, where it is expressed to produce the encoded product.
  • This can be accomplished by any of numerous methods known in the art, e.g., by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, e.g., by infection using a defective or attenuated retroviral or other viral vector (see U.S. Patent No.
  • a nucleic acid-ligand complex can be formed in which the ligand comprises a fusogenic viral peptide to disrupt endosomes, allowing the nucleic acid to avoid lysosomal degradation.
  • the nucleic acid can be targeted in vivo for cell-specific uptake and expression, by targeting a specific receptor (see, e.g., PCT Pubs. WO 92/06180 ; WO 92/22635 ; WO92/20316 ; WO93/14188 ; WO 93/20221 ).
  • the nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination ( Koller et al. (1989) Proc. Natl. Acad. Sci. U.S.A., 86:8932-8935 ; Zijlstra et al. (1989) Nature, 342:435-438 ).
  • a viral vector that contains an ERG or LTF nucleic acid is used.
  • a retroviral vector can be used (see, Miller et al. (1993) Meth. Enzymol., 217:581-599 ). These retroviral vectors have been modified to delete retroviral sequences that are not necessary for packaging of the viral genome and integration into host cell DNA.
  • the ERG or LTF nucleic acid to be used in gene therapy is cloned into the vector, which facilitates delivery of the gene into a patient. More detail about retroviral vectors can be found in Boesen et al.
  • Adenoviruses are other viral vectors that can be used in gene therapy. Adenoviruses are especially attractive vehicles for delivering genes to respiratory epithelia. Adenoviruses naturally infect respiratory epithelia where they cause a mild disease. Other targets for adenovirus-based delivery systems are liver, the central nervous system, endothelial cells, and muscle. Adenoviruses have the advantage of being capable of infecting non-dividing cells. Kozarsky et al. (1993, Curr. Opin. Gen. Devel., 3:499-503 ) present a review of adenovirus-based gene therapy. Bout et al. (1994, Hum.
  • Adeno-associated virus has also been proposed for use in gene therapy ( Walsh et al. (1993) Proc. Soc. Exp. Biol. Med., 204:289-300 ).
  • Another approach to gene therapy involves transferring a gene to cells in tissue culture by such methods as electroporation, lipofection, calcium phosphate mediated transfection, or viral infection.
  • the method of transfer includes the transfer of a selectable marker to the cells. The cells are then placed under selection to isolate those cells that have taken up and are expressing the transferred gene. Those cells are then delivered to a patient.
  • the nucleic acid is introduced into a cell prior to administration in vivo of the resulting recombinant cell.
  • introduction can be carried out by any method known in the art, including but not limited to transfection, electroporation, microinjection, infection with a viral or bacteriophage vector containing the nucleic acid sequences, cell fusion, chromosome-mediated gene transfer, microcell-mediated gene transfer, spheroplast fusion, etc.
  • Numerous techniques are known in the art for the introduction of foreign genes into cells (see, e.g., Loeffler et al. (1993) Meth. Enzymol., 217:599-618 ; Cohen et al. (1993) Meth.
  • the technique should provide for the stable transfer of the nucleic acid to the cell, so that the nucleic acid is expressible by the cell and preferably heritable and expressible by its cell progeny.
  • the resulting recombinant cells can be delivered to a patient by various methods known in the art.
  • epithelial cells are injected, e.g., subcutaneously.
  • recombinant skin cells may be applied as a skin graft onto the patient.
  • Recombinant blood cells e.g., hematopoietic stem or progenitor cells
  • the amount of cells envisioned for use depends on the desired effect, patient state, etc., and can be determined by one skilled in the art.
  • Cells into which a nucleic acid can be introduced for purposes of gene therapy encompass any desired, available cell type, and include, but are not limited to, epithelial cells, endothelial cells, keratinocytes, fibroblasts, muscle cells, hepatocytes, T lymphocytes, B lymphocytes, monocytes, macrophages, neutrophils, eosinophils, megakaryocytes, granulocytes; various stem or progenitor cells, in particular hematopoietic stem or progenitor cells, e.g., as obtained from bone marrow, umbilical cord blood, peripheral blood, fetal liver, etc.
  • the cells used for gene therapy are autologous to the patient.
  • an ERG or LTF nucleic acid or antisense molecule is introduced into the cells such that it is expressible by the cells or their progeny, and the recombinant cells are then administered in vivo for therapeutic effect.
  • stem or progenitor cells are used. Any stem and/or progenitor cells which can be isolated and maintained in vitro can potentially be used in accordance with this embodiment of the present invention.
  • Such stem cells include, but are not limited to, hematopoietic stem cells (HSC), stem cells of epithelial tissues such as the skin and the lining of the gut, embryonic heart muscle cells, liver stem cells ( PCT Pub. WO 94/08598 ), and neural stem cells ( Stemple et al. (1992) Cell, 71:973-985 ).
  • Epithelial stem cells (ESCs) or keratinocytes can be obtained from tissues such as the skin and the lining of the gut by known procedures ( Rheinwald (1980) Meth. Cell Bio., 21A:229 ). In stratified epithelial tissue such as the skin, renewal occurs by mitosis of stem cells within the germinal layer, the layer closest to the basal lamina. Stem cells within the lining of the gut provide for a rapid renewal rate of this tissue.
  • ESCs or keratinocytes obtained from the skin or lining of the gut of a patient or donor can be grown in tissue culture ( Rheinwald (1980) Meth. Cell Bio., 21A:229 ; Pittelkow et al. (1986) Mayo Clinic.
  • ESCs are provided by a donor, a method for suppression of host versus graft reactivity (e.g., irradiation, drug or antibody administration to promote moderate immunosuppression) can also be used.
  • a method for suppression of host versus graft reactivity e.g., irradiation, drug or antibody administration to promote moderate immunosuppression
  • HSC hematopoietic stem cells
  • any technique which provides for the isolation, propagation, and maintenance in vitro of HSC can be used. Techniques by which this may be accomplished include (a) the isolation and establishment of HSC cultures from bone marrow cells isolated from the future host, or a donor, or (b) the use of previously established long-term HSC cultures, which may be allogeneic or xenogeneic.
  • Non-autologous HSC may be used in conjunction with a method of suppressing transplantation immune reactions of the future host/patient.
  • human bone marrow cells can be obtained from the posterior iliac crest by needle aspiration (see, e.g., Kodo et al. (1984) J. Clin.
  • the HSCs can be made highly enriched or in substantially pure form. This enrichment can be accomplished before, during, or after long-term culturing, and can be done by any techniques known in the art.
  • Long-term cultures of bone marrow cells can be established and maintained by using, for example, modified Dexter cell culture techniques ( Dexter et al. (1977) J. Cell Physiol., 91:335 ) or Witlock-Witte culture techniques ( Witlock et al. (1982) Proc. Natl. Acad. Sci. U.S.A., 79:3608-3612 ).
  • compositions comprising an effective amount of an ERG or LTF therapeutic, including ERG or LTF nucleic acids (sense or antisense) or ERG or LTF polypeptides, in a pharmaceutically acceptable carrier, as described below.
  • compositions comprising an effective amount of a polypeptide of the present invention, in combination with other components such as a physiologically acceptable diluent, carrier, or excipient, are provided herein.
  • the polypeptides can be formulated according to known methods used to prepare pharmaceutically useful compositions. They can be combined in admixture, either as the sole active material or with other known active materials suitable for a given indication, with pharmaceutically acceptable diluents (e.g., saline, Tris-HCl, acetate, and phosphate buffered solutions), preservatives (e.g., thimerosal, benzyl alcohol, parabens), emulsifiers, solubilizers, adjuvants and/or carriers.
  • Suitable formulations for pharmaceutical compositions include those described in Remington's Pharmaceutical Sciences, 16th ed., Mack Publishing Company, Easton, PA, 1980 .
  • compositions can be complexed with polyethylene glycol (PEG), metal ions, or incorporated into polymeric compounds such as polyacetic acid, polyglycolic acid, hydrogels, dextran, etc., or incorporated into liposomes, microemulsions, micelles, unilamellar or multilamellar vesicles, erythrocyte ghosts or spheroblasts.
  • PEG polyethylene glycol
  • metal ions or incorporated into polymeric compounds such as polyacetic acid, polyglycolic acid, hydrogels, dextran, etc.
  • liposomes such as polyacetic acid, polyglycolic acid, hydrogels, dextran, etc.
  • Such compositions will influence the physical state, solubility, stability, rate of in vivo release, and rate of in vivo clearance, and are thus chosen according to the intended application.
  • compositions can be administered in any suitable manner, e.g., topically, parenterally, or by inhalation.
  • parenteral includes injection, e.g., by subcutaneous, intravenous, or intramuscular routes, also including localized administration, e.g., at a site of disease or injury. Sustained release from implants is also contemplated.
  • suitable dosages will vary, depending upon such factors as the nature of the disorder to be treated, the patient's body weight, age, and general condition, and the route of administration. Preliminary doses can be determined according to animal tests, and the scaling of dosages for human administration is performed according to art-accepted practices.
  • compositions comprising nucleic acids in physiologically acceptable formulations, e.g., to be used for gene therapy are also contemplated.
  • the nucleic acid can be administered in vivo to promote expression of the encoded protein, by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular as described in other sections herein.
  • Various delivery systems are known in the art and can be used to administer a therapeutic. Examples include, but are not limited to encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the therapeutic, receptor-mediated endocytosis (see, e.g., Wu et al. (1987) J. Biol. Chem., 262:4429-4432 ), construction of a therapeutic nucleic acid as part of a retroviral or other vector, etc.
  • Methods of introduction include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes.
  • the compounds may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local.
  • Pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent.
  • compositions may be desirable to administer the pharmaceutical compositions locally to the area in need of treatment; this may be achieved by, for example, local infusion during surgery, topical application, e.g., in conjunction with a wound dressing after surgery, by injection, by means of a catheter, a suppository, an implant, wherein the said implant is of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers.
  • administration can be by direct injection at the site (or former site) of a malignant tumor or neoplastic or pre-neoplastic tissue.
  • the therapeutic can be delivered in a vesicle, in particular a liposome (see Langer (1990) Science, 249:1527-1533 ; Treat et al. (1989) in Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein et al., eds., Liss, New York, pp. 353-365 ; Lopez-Berestein, ibid., pp. 317-327 .
  • the therapeutic can be delivered in a controlled release system.
  • a pump may be used (see Langer, supra; Sefton (1987) CRC Crit. Ref. Biomed. Eng., 14:201 ; Buchwald et al.
  • polymeric materials can be used (see Medical Applications of Controlled Release, Langer et al., eds., CRC Pres., Boca Raton, FL, 1974 ; Controlled Drug Bioavailability, Drug Product Design and Performance, Smolen et al., eds., Wiley, New York, 1984 ; Ranger et al. (1983) J. Macromol. Sci. Rev. Macromol. Chem., 23:61 ; see also Levy et al. (1985) Science, 228:190 ; During et al. (1989) Ann.
  • a controlled release system can be placed in proximity of the therapeutic target, i.e., the brain, thus requiring only a fraction of the systemic dose (see, e.g., Goodson (1984) in Medical Applications of Controlled Release, supra, vol. 2, pp. 115-138 ).
  • Other controlled release systems are discussed in the review by Langer (1990, Science, 249:1527-1533 ).
  • diagnostics Such molecules can be used in assays, such as immunoassays, to detect, prognose, diagnose, or monitor various conditions, diseases, and disorders affecting ERG, LTF, DD3, and/or AMACR expression, or monitor the treatment thereof, particularly cancer, and more particularly prostate cancer.
  • an immunoassay is carried out by a method comprising contacting a sample derived from an individual with an anti-ERG, anti-LTF, anti-DD3, and/or anti-AMACR antibody (directed against either a protein product or a nucliec acid) under conditions such that specific binding can occur, and detecting or measuring the amount of any specific binding by the antibody.
  • an anti-ERG, anti-LTF, anti-DD3, and/or anti-AMACR antibody directed against either a protein product or a nucliec acid
  • binding of antibody, in tissue sections can be used to detect aberrant ERG, LTF, DD3, and/or AMACR localization or aberrant (e.g., high, low or absent) levels of ERG, LTF, DD3, and/or AMACR.
  • antibody to ERG, LTF, DD3, and/or AMACR can be used to assay in a biological sample (e.g., tissue, blood, or urine sample) for the presence of ERG, LTF, DD3, and/or AMACR where an aberrant level of ERG, LTF, DD3, and/or AMACR is an indication of a diseased condition, such as cancer, including, for example, prostate cancer.
  • a biological sample e.g., tissue, blood, or urine sample
  • an aberrant level of ERG, LTF, DD3, and/or AMACR is an indication of a diseased condition, such as cancer, including, for example, prostate cancer.
  • tissue, cells, blood, lymph, semen, and urine can be used, including tissue, cells, blood, lymph, semen, and urine.
  • the biological sample is preferably derived from prostate tissue, blood, or urine.
  • the tissue sample comprises cells obtained from a patient. The cells may be found in a prostate tissue sample collected, for example, by a prostate tissue biopsy or histology section, or a bone marrow biopsy.
  • the blood sample can include whole blood, plasma, serum, or any derivative thereof, including, for example, circulating cells, such as prostate cells, isolated from the blood sample, or nucleic acid or protein obtained from the isolated cells.
  • Blood may contain prostate cells, particularly when the prostate cells are cancerous, and, more particularly, when the prostate cancer metastasizes and is shed into the blood.
  • the urine sample can be whole urine or any derivative thereof, including, for example, cells, such as prostate cells, obtained from the urine.
  • the immunoassays which can be used include, but are not limited to, competitive and non-competitive assay systems using techniques such as Western blots, radioimmunoassays, ELISA, immunoprecipitation assays, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, protein A immunoassays, to name but a few.
  • ERG, LTF, DD3, and/or AMACR genes and related nucleic acid sequences and subsequences, including complementary sequences, can also be used in hybridization assays.
  • ERG, LTF, DD3, and/or AMACR nucleic acid sequences, or subsequences thereof comprising about at least 8, 15, 20, 50, 100, 250, or 500 nucleotides can be used as hybridization probes.
  • Hybridization assays can be used to detect, prognose, diagnose, or monitor conditions, disorders, or disease states associated with aberrant changes in ERG, LTF, DD3, and/or AMACR expression and/or activity as described above.
  • such a hybridization assay is carried out by a method comprising contacting a sample containing nucleic acid with a nucleic acid probe capable of hybridizing under defined conditions (preferably under high stringency hybridization conditions, e.g., hybridization for 48 hours at 65°C in 6X SSC followed by a wash in 0.1X SSX at 50°C for 45 minutes) to an ERG, LTF, DD3, and/or AMACR nucleic acid, and detecting (i.e, measuring either qualitatively or quantitatively) the degree of the resulting hybridization.
  • a nucleic acid probe capable of hybridizing under defined conditions (preferably under high stringency hybridization conditions, e.g., hybridization for 48 hours at 65°C in 6X SSC followed by a wash in 0.1X SSX at 50°C for 45 minutes) to an ERG, LTF, DD3, and/or AMACR nucleic acid, and detecting (i.e, measuring either qualitatively or quantitatively) the degree of the resulting hybridization.
  • any nucleic acid amplification procedure including, PCR/RT-PCR, TMA, NASBA, 3SR, LCR, SDA, and LAMP can be used to detect the presence of the ERG, LTF, DD3 and/or AMACR gene and/or the level of its mRNA expression.
  • probes exhibiting at least some degree of self-complementarity are desirable to facilitate detection of probe: target duplexes in a test sample without first requiring the removal of unhybridized probe prior to detection.
  • Molecular torch probes are a type of self-complementary probes that are disclosed by Becker et al., U.S. Patent No. 6,361,945 .
  • the molecular torch probes disclosed Becker et al. have distinct regions of self-complementarity, referred to as "the target binding domain” and "the target closing domain,” which are connected by a joining region and which hybridize to one another under predetermined hybridization assay conditions.
  • the complementary regions (which may be fully or partially complementary) of the molecular torch probe melt, leaving the target binding domain available for hybridization to a target sequence when the predetermined hybridization assay conditions are restored. And when exposed to strand displacement conditions, a portion of the target sequence binds to the target binding domain and displaces the target closing domain from the target binding domain.
  • Molecular torch probes are designed so that the target binding domain favors hybridization to the target sequence over the target closing domain.
  • the target binding domain and the target closing domain of a molecular torch probe include interacting labels (e.g ., luminescent/quencher) positioned so that a different signal is produced when the molecular torch probe is self-hybridized as opposed to when the molecular torch probe is hybridized to a target nucleic acid, thereby permitting detection of probe: target duplexes in a test sample in the presence of unhybridized probe having a viable label or labels associated therewith.
  • interacting labels e.g ., luminescent/quencher
  • Molecular beacon probes include nucleic acid molecules having a target complement sequence, an affinity pair (or nucleic acid arms) holding the probe in a closed conformation in the absence of a target nucleic acid sequence, and a label pair that interacts when the probe is in a closed conformation.
  • Hybridization of the target nucleic acid and the target complement sequence separates the members of the affinity pair, thereby shifting the probe to an open confirmation.
  • the shift to the open confirmation is detectable due to reduced interaction of the label pair, which may be, for example, a fluorophore and quencher, such as DABCYL and EDANS.
  • ERG, LTF, AMACR, or DD3 hybridization probes can comprise a nucleic acid having a contiguous stretch of at least about 8, 15, 20, 50, 100, 250, 500, 750, 1000, 1250, or 1500 contiguous nucleotides of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5 or a sequence complementary thereto.
  • Such contiguous fragments of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5 may also contain at least one mutation so long as the mutant sequence retains the capacity to hybridize to SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO: 3, SEQ ID NO:4, or SEQ ID NO:5 under low or high stringency conditions (preferably under high stringency hybridization conditions, e.g., hybridization for 48 hours at 65°C in 6X SSC followed by a wash in 0.1X SSX at 50°C for 45 minutes).
  • diseases and disorders involving hyperproliferation of cells can be diagnosed, or their suspected presence can be screened for, or a predisposition to develop such disorders can be predicted, by detecting levels of the ERG, LTF, and/or AMACR protein, ERG, DD3, and/or AMACR RNA, or ERG, DD3, and/or AMACR functional activity, or by detecting mutations in ERG, DD3, LTF and/or AMACR RNA, DNA, or protein (e.g., translocations in ERG, LFT, DD3, or AMACR nucleic acids, truncations in the ERG, LFT, DD3, or AMACR gene or protein, changes in nucleotide or amino acid sequence relative to wild-type ERG, LTF, DD3, or AMACR) that cause increased or decreased expression or activity of ERG, LTF, DD3, and/or AMACR.
  • ERG, LTF, and/or AMACR protein ERG, DD3, and/or AMACR
  • levels of ERG, LTF, and/or AMACR protein can be detected by immunoassay
  • levels of ERG, LTF, DD3, and/or AMACR mRNA can be detected by hybridization assays (e.g., Northern blots, dot blots, or any nucleic acid amplification procedure, including, PCR/RT-PCR, TMA, NASBA, 3SR, LCR, SDA, and LAMP)
  • translocations and point mutations in ERG, LTF, DD3, and/or AMACR nucleic acids can be detected by Southern blotting, RFLP analysis, any nucleic acid amplification procedure, including, PCR/RT-PCR, TMA, NASBA, 3SR, LCR, SDA, LAMP, sequencing of the ERG, LTF, DD3, and/or AMACR genomic DNA or cDNA obtained from the patient, etc.
  • levels of the ERG, DD3, LTF and/or AMACR mRNA or protein in a subject sample are detected or measured and compared to the mRNA or protein expression levels of the corresponding gene in a control sample or to a standard numerical value or range.
  • increased expression levels of ERG, DD3, and/or AMACR or decreased levels of LTF, relative to a matched, normal tissue sample indicate that the subject has a malignancy or hyperproliferative disorder, including, for example, prostate cancer, or a predisposition to develop the same.
  • Other appropriate controls include other noncancerous samples from the subject, samples obtained from a different subject without cancer, or other cancer-specific markers.
  • a prostate-cell specific marker such as PSA
  • PSA can be used as a control to compare and/or normalize expression levels of other genes, such as ERG, LTF, DD3, and/or AMACR.
  • a method of diagnosing cancer comprises obtaining a biological sample from a subject (e.g., a tissue sample (e.g., from biopsy tissue), a blood sample, or a urine sample), determining the expression level of a ERG, LTF, DD3, and/or AMACR gene and/or ERG, LTF, DD3, and/or AMACR activity in the samples, and diagnosing or prognosing cancer in said subject.
  • the expression level of the ERG, LTF, DD3, and/or AMACR gene and/or ERG, LTF, DD3, and/or AMACR activity is determined by Southern blotting, Northern blotting, Western blotting, ELISA, any nucleic acid amplification procedure, including, PCR/RT-PCR, TMA, NASBA, 3SR, LCR, SDA, and LAMP, or other techniques as described herein or known in the art.
  • increased or decreased expression of at least two times, as compared to the control sample indicates the presence of prostate cancer or a higher predisposition to developing prostate cancer.
  • Kits for diagnostic use are also provided.
  • a kit comprises an anti-ERG gene antibody or an antibody directed against the ERG protein and/or an anti-AMACR gene antibody or an antibody directed against the AMACR protein and/or an anti-DD3 gene antibody and/or and an anti-LTF gene antibody or an antibody directed against the LTF protein,which can be optionally detectably labeled.
  • a kit is also provided that comprises a nucleic acid probe capable of hybridizing under defined conditions (preferably under high stringency hybridization conditions, e.g., hybridization for 48 hours at 65°C in 6X SSC followed by a wash in 0.1X SSX at 50°C for 45 minutes) to ERG, LTF, DD3, and/or AMACR nucleic acid.
  • a kit comprises at least a pair of primers (e.g., each in the size range of at least about 6, 17, 30, or 60 nucleotides) that are capable of priming amplification, by any nucleic acid amplification procedure (including e.g., PCR/RT-PCR, TMA, NASBA, 3SR, LCR, SDA, LAMP), of the ERG, LTF, DD3, and/or AMACR gene or a fragment thereof.
  • a kit can comprise a predetermined amount of a purified ERG, LTF, DD3, and/or AMACR protein or nucleic acid for use, e.g., as a standard or control.
  • the kit can also comprise one or more components for detecting the nucleic acid probe, including components described herein or known in the art.
  • the kit comprises a nucleic acid that hybridizes under defined conditions (and preferably under conditions of high stringency, e.g., hybridization for 48 hours at 65°C in 6X SSC followed by a wash in 0.1X SSX at 50°C for 45 minutes) with at least one gene chosen from those genes identified in Tables 1-6 or the DD3 gene, and is affixed to a support, alone, or in combination with other nucleic acids.
  • an ERG and/or LTF nucleic acid can be affixed to the support, with or without other nucleic acids.
  • the support comprises at least an ERG nucleic acid and an AMACR nucleic acid or at least an ERG nucleic acid and a DD3 nucleic acid. In another embodiment, the support comprises at least an ERG nucleic acid, an AMACR nucleic acid, and a DD3 nucleic acid. This support can be used as part of a kit for detecting cancer, such as prostate cancer.
  • kits can further comprise at least a pair of primers (e.g., each in the size range of at least about 6, 17, 30, or 60 nucleotides) that are capable of priming amplification, by any nucleic acid amplification procedure (including e.g., PCR/RT-PCR, TMA, NASBA, 3SR, LCR, SDA, LAMP), of the ERG, LTF, DD3, and/or AMACR gene or a fragment thereof.
  • primers e.g., each in the size range of at least about 6, 17, 30, or 60 nucleotides
  • Example 1 Screening of CaP cell-specific gene expression signatures using Affymetrix GeneChip
  • Specimens were obtained under an IRB-approved protocol from patients treated by radical prostatectomy (RP) at Walter Reed Army Medical Center (WRAMC). From over 300 patients two groups were selected which had prostate tumors with either moderate (MR) or high risk (HR) of disease progression after RP.
  • the HR group had PSA recurrence, Gleason score 8-9, T3c stage, seminal vesicle invasion, and poorly differentiated tumor cells;
  • the MR group had no PSA recurrence, Gleason score 6-7, T2a-T3b stage, no seminal vesicle invasion, and well to moderately differentiated tumor cells.
  • LCM compatible specimens were selected from age and race matched HR or MR patients with no family history of CaP.
  • LCM laser capture microdissected
  • H&E Hematoxylin-eosin
  • HG U133A array high-density oligonucleotide human genome array
  • EST expressed sequence tags
  • Biotinylation was carried out using aRNA by in vitro transcription using MEGA script T7 in vitro Transcription Kit (Ambion, Austin, TX, USA) cDNA and biotinylated UTP and biotinylated CTP (ENZO, Farmingdale, NY, USA)(34).
  • the biotin labeled cRNA was purified using the QIAGEN RNeasy spin columns (QIAGEN, Valencia, CA) following the manufacturer's protocol.
  • the biotin labeled cRNA was fragmented in a 40 ⁇ l reaction mixture containing 40 mM Tris-acetate, pH 8.1, 100 mM potassium acetate, and 30 mM magnesium acetate incubated at 94°C for 35 minutes and then put on ice.
  • the biotin labeled and fragmented aRNA was hybridized to the HG U133A array. Briefly, a 220 ⁇ l hybridization solution consisting of: 1M NaCl, 10 mM Tris pH 7.6, 0.005% Triton X-100, 50 pM control Oligo B2 (5' bioGTCAAGATGCTACCGTTCAG 3') (SEQ ID NO:6) (Affymetrix); the control cRNA cocktail of: Bio B (150 pM), Bio C (500 pM), Bio D (2.5 nM) and Cre X (10 nM) (American Type Tissue Collection, Manassas,VA and Lofstrand Labs, Gaithersburg, MD), 0.1 mg/ml herring sperm DNA and 0.05 ⁇ g/ ⁇ l of the fragmented labeled sample cRNA was heated to 95°C for 35 min., cooled to 40°C and clarified by centrifugation.
  • Hybridization was at 42°C in a rotisserie hybridization oven (Model 320, Affymetrix) at 60 rpm for 16 hours. Following hybridization, the GeneChip arrays were washed 10 times at 25°C with 6X SSPE-T buffer (1 M NaCl, 0.006 M EDTA, and 0.06 M Na 3 PO 4 , 0.005% Triton X-100, pH 7.6) using the automated fluidics station protocol. GeneChip arrays were incubated at 50°C in 0.5X SSPE-T, 0.005% Triton X-100 for 20 minutes at 60 rpm in the rotisserie oven.
  • GeneChip arrays were stained for 15 minutes at room temperature and at 60 rpm, with streptavidin phycoerythrin (Molecular Probes, Inc., Eugene, OR) stain solution at a final concentration of 10 ⁇ g/ml in 6X SSPE-T buffer and 1.0 mg/ml acetylated bovine serum albumin (Sigma). GeneChip arrays were washed twice at room temperature with 6X SSPE-T buffer, and then were scanned with the HP GeneArray Scanner (Hewlett-Packard, Santa Clara, CA) controlled by GeneChip 3.1 Software (Affymetrix).
  • Affymetrix GeneChip Microarray Analysis Software version 3.1 and Affymetrix Micro DB and Data Mining Tool version 2.0 (Affymetrix), Microsoft Excel 2000 (Microsoft, Seattle, WA) and Statistica version 4.1 (Stat Soft, Inc., Tulsa, OK) were used.
  • Affymetrix the average difference fluorescence is the average of the difference between every perfect match probe cell and its control mismatch probe cell and is directly related to the level of expression of a transcript.
  • a comparative file indicates the relative change in abundance (fold change) for each transcript between a baseline and an experimental sample.
  • Microarray Data Analysis software from NHGRI and the GeneSpring software (Silicon Genetics, CA).
  • NHGRI National Human Genome Research Institute
  • MDS multidimensional scaling
  • Genes were ranked according to their w values. Genes with high w values created greater separation between groups and denser compaction within the group. In other words, the subset of genes with high w values have the most discriminative power to differentiate a high risk group from a moderate risk group and vice versa. Sample labels were randomly permuted and the w value was computed again for each gene to test the statistical significance of the discriminative weights. Genes with the most significant expression differences were selected by p-values. A hierarchical clustering algorithm was used to verify the predictor model obtained from the supervised MDS analysis.
  • NM_000441 0.392117 PDS, DFNB4 Solute carrier family 26, member 4 7q31 17.
  • AL031602 0.399115 ESTs ESTs 1p34.1-35.3 18.
  • NM_004039 0.399796 ANXA2 Annexin A2 15q21-q22 19.
  • NM_001546 0.402261
  • ID4 DNA binding inhibitor protein of ID-4 6p22-p21 20.
  • NM_001099 0.406234 PAP Acid phosphatase, prostate 3q21-q23 21.
  • X57348 0.422692 9112 H.sapiens mRNA (clone 9112). 1p35.2 22.
  • NM_020139 0.440648 LOC56898 Oxidoreductase UCPA 4 23. AU148057 0.444528 DKK3, REIC Dickkopf related protein-3 precursor (Dkk-3) (Dickkopf-3) (hDkk-3) 11pter-p15.5 24. BF059159 0.446108 ROBO1, DUTT1, SAX3 Roundabout, axon guidance receptor, homolog 1 (Drosophila) 3p12 25. BC001120 0.448109 MAC2, GALBP, MAC-2, Lectin, galactoside-binding, soluble, 3 (galectin 3) 14q21-q22 26.
  • a class prediction analysis using distance based Multi Dimensional Scaling (MDS) was used to determine expression differences between tumor and benign epithelial cells in 18 patients with radical prostatectomy. All the genes that meet a minimum level of expression were included in the analysis.
  • MDS Multi Dimensional Scaling
  • Using a matrix of Pearson correlation coefficients from the complete pair-wise comparison of all the experiments we observed a significant overall difference in gene expression pattern between the tumor and benign tissue as displayed as a two-dimensional MDS plot in Figure 2A .
  • the position of the each tumor and benign samples is displayed in the MDS plot in two-dimensional Euclidean space with the distance among the samples reflecting correlation among the samples in each individual group (distance within the cluster) and as well as reflecting distinct separation between the two groups (center-to center distance) ( Figure 2A ).
  • the MDS plot was obtained from the top 200 genes obtained by 10,000 permutations of the tumor and benign intensities of 4566 genes. Out of these 200 genes that define the tumor specific alteration of gene expression, 53 genes had higher expression in the tumor samples and the remaining 147 genes had higher expression in the benign samples.
  • Table 1 A partial list of genes that distinctly discriminate the tumor and benign samples from all the 18 patients is shown in Table 1.
  • the hierarchical clustering algorithm resulted in a hierarchical dendrogram that identified two major distinct clusters of 16 tumor samples and 17 benign samples ( Figure 2B ).
  • T/B ratio tumor over benign gene expression intensity ratio
  • Figure 3A We used the tumor over benign gene expression intensity ratio (T/B ratio) from the HR (9 patients) and MR (9 patients) groups for a class prediction analysis using distance based MDS method to determine if the 18 patients can be differentiated into the two patient groups. Pathological and clinical features of the 18 tumors used in our study were clearly distinguishable between the HR and MR groups. We observed a significant overall difference in expression pattern between the HR and MR groups. The distance between the samples reflects both the extent of correlation within each individual selected group (distance within the cluster) as well as distinct separation between the two selected groups (center-to-center distance) ( Figure 3A ).
  • the MDS plot obtained from top 200 genes by 10,000 permutations of the 4868 genes based on the T/B ratio is shown in Figure 3A .
  • Out of the top 200 genes of the MDS analysis 135 were over expressed in the HR group and 65 genes were over expressed in the MR group,
  • the top 50 genes with best p-values identified by the T/B ratio based MDS analysis discriminating the HR and MR groups are listed in Figure 3B .
  • the approach we used for the interpretation of discrimination between the HR and MR groups was empirical.
  • the 'weighted list' ( Figure 3B ) of individual genes whose variance of change across all the tumor samples defines the boundary of a given cluster to predict a class that correlates with the pathological and clinical features of CaP.
  • MDS analysis was used to determine differentiation among 18 patients into HR and MR groups.
  • An overall difference in tumor specific expression between the HR and MR groups is displayed as a two-dimensional MDS plot ( Figure 3C ).
  • the MDS plot obtained from 10,000 permutations of the gene expression intensities of 4115 genes from the tumor samples of 18 patients differentiated them into HR and MR groups based on the selected top 200 genes ( Figure 3C ). Out of this 200 genes, 94 had higher expression in the HR groups and the remaining 106 genes had higher expression in the MR groups.
  • the 'weighted list' of individual genes whose variance of expression alteration across all the normal samples depicts the capability of a given cluster to predict classification.
  • the hierarchical clustering algorithm identified a similar major cluster of the 9 benign samples of the HR group and a cluster of 9 benign samples of the MR group.
  • the weighted gene analysis by distance based supervised multidimensional scaling method we used, (depicted in Figure 3A , 3C , and 3E ) utilizing the gene expression ratio of tumor and benign intensities, gene expression intensities of tumor samples and as well as normal for obtaining a 'weighted list' of individual genes, whose variance of change across all the tumor and benign samples distinctly delineate the boundary of a given cluster, to predict a class that correlates with the pathological and clinical features of CaP.
  • RNA samples from paired tumor and normal specimens was reverse-transcripted using Omnisensecript RT-kit (Qiagene, Valencia, CA) according to the manufacturer's protocol.
  • Quantitative gene expression analysis was performed using TaqMan Master Mix Reagent and an ABI prism 7700 Sequence Detection System (PE Applied Biosystems Foster, CA). All sets of primer and probe for tested genes were Assays-on-Demand Gene expression products obtained from PE Applied Biosystems. The expression of house keeping gene, GAPDH was simultaneously analyzed as the endogenous control of same batch of cDNA, and the target gene expression of each sample was normalized to GAPDH. For each PCR run, a master-mix was prepared on ice with 1 x TaqMan Master Mix, 1x target gene primer/probe and 1x GAPDH primer/probe. Two microliters of each diluted cDNA sample was added to 28 ⁇ l of PCR master-mix.
  • the thermal cycling conditions comprised an initial denaturation step at 95 ⁇ C for 10 minutes and 50 cycles at 95 ⁇ C for 15 seconds and 60 ⁇ C for 1 minute.
  • RNA samples without reverse transcription were included as the negative control in each assay. All assays were performed in duplicate. Results were plotted as average C T (threshold cycle) of duplicated samples.
  • the Affymetrix GeneChip probe set (213541_s_at) and TaqMan probes used in the experiments described above recognize a region specific for both ERG1 and ERG2 isoforms ( Figure 6 ), but exclude isoforms 3 to 9.
  • TaqMan primers and probe recognizing both ERG1 and ERG2 but not other ERG isoforms were as follows:
  • ERG1 and ERG2 isoforms were tested in PC3 cells and in normal prostate tissue (pooled prostate RNA from 20 men, Clontech), as well as in microdissected tumor and normal prostate epithelial cells from 5 CaP patients (data not shown). Only ERG1 was expressed in the prostate cells and in PC3 cells. ERG2 expression was not detectable.
  • a TaqMan QRT-PCR probe and primers were designed that specifically recognize only the ERG1 isoform ( Figure 6 ). Although other primers and probes could be used, by way of example, we designed TaqMan primers and probes recognizing only the ERG1 isoform as follows:
  • ERG1 expression was determined in 228 RNA specimens from microdissected matched tumor and benign prostate epithelial cells of 114 CaP patients. Overall, 62.4% of the 114 CaP patients analyzed had significant over expression of ERG1 isoform in their tumor cells (i.e., greater than 2 fold ERG1 expression in tumor versus benign cells), while 16.6% of CaP patients had no detectable ERG1 expression, 15.0% had under expression of ERG1 (less than 0.5 fold difference in ERG1 expression in tumor versus benign cells), and 6.0% had no significant difference (0.5 to 2 fold difference in ERG1 expression between tumor versus benign cells).
  • ERG expression was analyzed in 82 CaP patients. Using the TaqMan primers and probes discussed above, we observed tumor-associated over expression of ERG1 (isoform 1 only) and ERG (isoforms 1 and 2) in 63.4% and 72.0% of the patients, respectively. Therefore, ERG1 isoform specific expression may actually reflect an underestimate of the overall ERG expression in CaP.
  • ERG1 cDNA was subcloned into tetracycline-regulated mammalian expression vectors (pTet-off, EC1214A).
  • the constructs generated include, pTet-off-ERG1 (sense), pTet-off-ERG1 (antisense), pTet-off-FlagERG1 (sense) and pTet-off-FlagERG1 (antisense).
  • pTet-off-ERG1 sense
  • pTet-off-ERG1 antisense
  • pTet-off-FlagERG1 antisense
  • ERG1 construct in a riboprobe vector pGEM was obtained from Dr. Dennis K. Watson, Medical University of South Carolina. The constructs were verified by dideoxy sequencing and agarose gel analysis.
  • Antibodies against ERG were generated using peptide antigens derived from the full length ERG1 coding sequence. The epitope for the antigen were carefully selected such that the antibody recognizes specifically ERG1/2/3 and not other members of the ETS family ( Figure 9 ). The following peptides, having the highest hydrophilicity (-1.26 and -0.55) and antigenicity in the desired region, were used to generate antibodies:
  • HEK-293 Human embryonic kidney cell line, ATCC, Manassas, VA
  • HEK-293 that were not transfected with the plasmid served as a transfection control. The cells were harvested 48 hours post-transfection and processed for immunoblot analysis.
  • ERG1 expression was determined by immunoblotting using the affinity purified polyclonal antisera generated against the unique M- and C-ERG epitopes described above. Endogenous ERG1 expression was not detected in non-transfected HEK-293 cells. However, the ERG antibodies detected ERG1 expression in HEK-293 cells transfected with the various ERG1 constructs. Tetracycline (2 ug/ml) abolished ERG1 expression in both tetracycline-regulated constructs, pTet-off-ERGl (sense) and pTet-off-FlagERG1 (sense). The M2-Flag antibody specifically recognized only the Flag-tagged ERG1 protein.
  • AMACR TaqMan primers and probe were purchased from Applied Biosystems.
  • AMACR and DD3 showed upregulation in tumor cells of 78.2% and 87.3% of CaP patients, respectively ( Figure 5 ).
  • ERG over expression in tumor cells was detected in 78.2% of the same group of CaP patients ( Figure 5 ).
  • Comparative expression analysis revealed that when the AMACR and ERG expression data are combined, 96.4% of the CaP patients showed upregulation of either of the two genes in tumor cells ( Figure 5 ).
  • the combination of the ERG and DD3 expression data improved the cancer detection power of either of the genes to 96.4% ( Figure 5 ).
  • 98.2% of the CaP patients showed upregulation of at least one of the three genes in tumor cells ( Figure 5 ).
  • LTF expression was analyzed by QRT-PCR in in microdissected tumor and benign prostate epithelial cells of 103 CaP patients. The results were consistent with the initial results, showing tumor associated under expression in 76% of patients (78 of 103).
  • LTF under expression was also validated at the protein level with anti-LTF goat polyclonal antibody (Santa Cruz, CA, sc-14434) using Western blot analysis on protein lysates and immunohistochemistry techniques. Hematotoxylin-eosin (H&E) and LTF staining was performed on tissue samples from 30 CaP patients by immunocytochemical analysis. In 30 of 30 (100%) cases, benign epithelial cells adjacent to tumor cells were highly positive for LTF, whereas, on average, less than 10% of prostate tumor cells revealed LTF positive cytoplasmic staining.
  • H&E Hematotoxylin-eosin
  • LTF staining was performed on tissue samples from 30 CaP patients by immunocytochemical analysis. In 30 of 30 (100%) cases, benign epithelial cells adjacent to tumor cells were highly positive for LTF, whereas, on average, less than 10% of prostate tumor cells revealed LTF positive cytoplasmic staining.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Claims (19)

  1. Verfahren zum Diagnostizieren von Prostatakrebs bei einer Person oder einer höheren Prädisposition der Person, Prostatakrebs auszubilden, wobei das Verfahren umfasst:
    (a) Messen des Expressionsniveaus eines ERG-Gens in einer biologischen Probe von der Person, wobei das ERG-Gen sowohl ERG1 (SEQ ID NO: 1) als auch ERG2 (SEQ ID NO: 2) umfasst;
    (b) Korrelieren des Expressionsniveaus des ERG-Gens mit der Anwesenheit von Prostatakrebs oder einer höheren Prädisposition der Person, Prostatakrebs auszubilden, wobei die erhöhte Expression des ERG-Gens in der biologischen Probe im Vergleich mit der Expression des ERG-Gens in einer Kontrollprobe oder mit einem standardisierten Wert mit der Anwesenheit von Prostatakrebs oder einer höheren Prädisposition der Person, Prostatakrebs auszubilden, korreliert.
  2. Verfahren nach Anspruch 1, wobei das Expressionsniveau des ERG-Gens durch eine oder mehrere Verfahren gemessen wird, die aus Immunhistochemie, Western Blot, ELISA, Immunassay, Southern Blot, Northern Blot und einer Nukleinsäureamplifizierungsprozedur gewählt werden.
  3. Verfahren nach Anspruch 1 oder 2, wobei das Expressionsniveau des ERG-Gens unter Verwendung einer Oligonucleotid-Sonde, die unter hohen Stringenzbedingungen mit SEQ ID NO: 1 und mit SEQ ID NO: 2 hybridisieren kann, oder unter Verwendung einer Nukleinsäureamplifizierungsprozedur und einer Oligonucleotid-Sonde, die unter hohen Stringenzbedingungen mit SEQ ID NO: 1 und mit SEQ ID NO: 2 hybridisieren kann, detektiert wird.
  4. Verfahren nach Anspruch 3, wobei die Oligonucleotid-Sonde unter hohen Stringenzbedingungen, die die Hybridisierung bei 65 °C in 6X SSC für 48 Stunden, gefolgt von einem Spülen bei 50 °C in 0,1X SSX für 45 Minuten, umfassen, hybridisieren kann.
  5. Verfahren nach einem der Ansprüche 1-4, wobei die Kontrollprobe eine nichtkanzeröse biologische Probe von der Person ist.
  6. Verfahren nach einem der Ansprüche 1 bis 5, wobei die Expression des LTF-Gens ebenfalls detektiert wird.
  7. Verfahren nach einem der Ansprüche 1-5, wobei das Expressionsniveau des ERG-Gens durch Nukleinsäureamplifizierung einer ERG-Nukleinsäure gemessen wird und wobei die ERG-Nukleinsäure RNA ist.
  8. Verfahren nach einem der Ansprüche 1-7, das umfasst:
    (a) Messen des Expressionsniveaus eines ERG-Gens und eines AMACR-Gens (SEQ ID NO: 3) in einer biologischen Probe von der Person, wobei das ERG-Gen ERG1 (SEQ ID NO: 1) und ERG2 (SEQ ID NO: 2) umfasst; und
    (b) Korrelieren des Expressionsniveaus des ERG-Gens und des AMACR-Gens mit der Anwesenheit von Prostatakrebs bei der Person oder einer höheren Prädisposition der Person, Prostatakrebs auszubilden, wobei eine erhöhte Expression des ERG-Gens und des AMACR-Gens in der biologischen Probe im Vergleich mit der Expression des ERG-Gens und des AMACR-Gens in einer Kontrollprobe oder mit einem standardisierten Wert mit der Anwesenheit von Prostatakrebs bei der Person oder mit einer höheren Prädisposition der Person, Prostatakrebs auszubilden, korreliert.
  9. Verfahren nach Anspruch 8, das ferner das Messen des Expressionsniveaus des DD3-Gens (SEQ ID NO: 4) und das Korrelieren des Expressionsniveaus des ERG-Gens, des AMACR-Gens und des DD3-Gens mit der Anwesenheit von Prostatakrebs bei der Person oder mit einer höheren Prädisposition der Person, Prostatakrebs auszubilden, umfasst, wobei die erhöhte Expression des ERG-Gens, des AMACR-Gens und des DD3-Gens in der biologischen Probe im Vergleich mit der Expression des ERG-Gens, des AMACR-Gens und des DD3-Gens in der Kontrollprobe oder mit dem standardisierten Wert mit der Anwesenheit von Prostatakrebs bei der Person oder mit einer höheren Prädisposition der Person, Prostatakrebs auszubilden, korreliert.
  10. Verfahren nach einem der Ansprüche 1-7, das umfasst:
    (a) Messen des Expressionsniveaus eines ERG-Gens und des DD3-Gens (SEQ ID NO: 4) in einer biologischen Probe von der Person; und
    (b) Korrelieren des Expressionsniveaus des ERG-Gens und des DD3-Gens mit der Anwesenheit von Prostatakrebs bei der Person oder mit einer höheren Prädisposition der Person, Prostatakrebs auszubilden, wobei eine erhöhte Expression des ERG-Gens und des DD3-Gens in der biologischen Probe im Vergleich mit der Expression des ERG-Gens und des DD3-Gens in einer Kontrollprobe oder mit einem standardisierten Wert mit der Anwesenheit von Prostatakrebs bei der Person oder mit einer höheren Prädisposition der Person, Prostatakrebs auszubilden, korreliert.
  11. Verfahren nach einem der Ansprüche 8-10, wobei das Expressionsniveau des ERG-Gens, des AMACR-Gens und/oder des DD3-Gens durch ein oder mehrere Verfahren gemessen wird, die aus Immunhistochemie, Western Blot, ELISA, Immunassay, Southern Blot, Northern Blot und einer Nukleinsäureamplifizierungsprozedur gewählt werden.
  12. Verfahren nach einem der Ansprüche 1-5 und 8-11, wobei die biologische Probe aus einer Prostatagewebeprobe, aus einer Blutprobe oder aus einer Urinprobe gewählt wird.
  13. Verwenden eines Kits in dem Verfahren nach Anspruch 8, wobei das Kit umfasst:
    eine erste Oligonucleotid-Sonde, die unter Bedingungen hoher Stringenz mit SEQ ID NO: 1 oder mit einer dazu komplementären Sequenz hybridisieren kann,
    eine zweite Oligonucleotid-Sonde, die unter Bedingungen hoher Stringenz mit SEQ ID NO: 3 oder mit einer dazu komplementären Sequenz hybridisieren kann, wobei die erste und die zweite Oligonucleotid-Sonde optional an einem Träger fixiert sind, und
    einen Standard oder eine Kontrolle, wobei der Standard oder die Kontrolle eine ERG-, eine DD3 und/oder eine AMACR-Nukleinsäure umfasst.
  14. Verwenden eines Kits in dem Verfahren nach Anspruch 10, wobei das Kit umfasst:
    eine erste Oligonucleotid-Sonde, die unter Bedingungen hoher Stringenz mit SEQ ID NO: 1 oder mit SEQ ID NO: 2 oder mit einer dazu komplementären Sequenz hybridisieren kann,
    eine zweite Oligonucleotid-Sonde, die unter Bedingungen hoher Stringenz mit SEQ ID NO: 4 oder mit einer dazu komplementären Sequenz hybridisieren kann, wobei die erste und die zweite Oligonucleotid-Sonde optional an einem Träger fixiert sind, und
    einen Standard oder eine Kontrolle, wobei der Standard oder die Kontrolle eine ERG-, eine DD3- und/oder eine AMACR-Nukleinsäure umfasst.
  15. Verwenden eines Kits nach Anspruch 13, wobei das Kit ferner eine dritte Oligonucleotid-Sonde, die unter Bedingungen hoher Stringenz mit SEQ ID NO: 4 (DD3) oder mit einer dazu komplementären Sequenz hybridisieren kann, umfasst, wobei die erste, die zweite und die dritte Oligonucleotid-Sonde optional an einem Träger fixiert sind.
  16. Verwenden eines Kits nach einem der Ansprüche 13-15, wobei die erste Oligonucleotid-Sonde mindestens etwa 20 zusammenhängende Nukleotide der SEQ ID NO: 1 oder der SEQ ID NO: 2 oder einer dazu komplementären Sequenz umfasst.
  17. Verwenden eines Kits nach Anspruch 16, wobei das Kit ferner einen ersten Oligonucleotid-Primer und einen zweiten Oligonucleotid-Primer umfasst, wobei der erste Oligonucleotid-Primer eine Sequenz enthält, die mit einer ersten Sequenz in der SEQ ID NO: 1 oder in der SEQ ID NO: 2 hybridisiert, und wobei der zweite Oligonucleotid-Primer eine Sequenz enthält, die mit einer zweiten Sequenz in einem Nukleinsäurestrang, der zu SEQ ID NO: 1 oder SEQ ID NO: 2 komplementär ist, hybridisiert, wobei die erste Sequenz mit der zweiten Sequenz nicht überlappt und wobei der erste und der zweite Oligonucleotid-Primer eine Zielsequenz in SEQ ID NO: 1 oder in SEQ ID NO: 2 amplifizieren können.
  18. Verwenden eines Kits nach einem der Ansprüche 13-17, wobei die erste und die zweite Oligonucleotid-Sonde unter hohen Stringenzbedingungen, die die Hybridisierung bei 65 °C in 6X SSC für 48 Stunden, gefolgt von einem Spülen bei 50 °C in 0,1X SSX für 45 Minuten, umfassen, hybridisieren können.
  19. Verwenden eines Kits nach einem der Ansprüche 13-17, wobei das Kit außerdem eine Oligonucleotid-Sonde umfasst, die unter Bedingungen hoher Stringenz mit der Nukleinsäuresequenz von LTF (SEQ ID NO: 5) oder mit einer dazu komplementären Sequenz hybridisieren kann, wobei die Oligonucleotid-Sonde optional an einem Träger fixiert ist.
EP11172817.6A 2004-05-07 2005-05-06 Verfahren zur diagnose oder behandlung von prostatakrebs mittels erg-gen, alleine oder in kombination mit anderen ober- oder unterexprimierten genen bei prostatakrebs Active EP2383350B1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US56882204P 2004-05-07 2004-05-07
US62202104P 2004-10-27 2004-10-27
EP05779973.6A EP1747292B1 (de) 2004-05-07 2005-05-06 Verfahren zur diagnose oder behandlung von prostatakrebs mittels erg-gen, alleine oder in kombination mit anderen ober- oder unterexprimierten genen bei prostatakrebs
PCT/US2005/015926 WO2005113816A2 (en) 2004-05-07 2005-05-06 Methods of diagnosing or treating prostate cancer using the erg gene, alone or in combination with other over or under expressed genes in prostate cancer

Related Parent Applications (3)

Application Number Title Priority Date Filing Date
EP05779973.6 Division 2005-05-06
EP05779973.6A Division-Into EP1747292B1 (de) 2004-05-07 2005-05-06 Verfahren zur diagnose oder behandlung von prostatakrebs mittels erg-gen, alleine oder in kombination mit anderen ober- oder unterexprimierten genen bei prostatakrebs
EP05779973.6A Division EP1747292B1 (de) 2004-05-07 2005-05-06 Verfahren zur diagnose oder behandlung von prostatakrebs mittels erg-gen, alleine oder in kombination mit anderen ober- oder unterexprimierten genen bei prostatakrebs

Publications (2)

Publication Number Publication Date
EP2383350A1 EP2383350A1 (de) 2011-11-02
EP2383350B1 true EP2383350B1 (de) 2018-07-11

Family

ID=35428942

Family Applications (2)

Application Number Title Priority Date Filing Date
EP11172817.6A Active EP2383350B1 (de) 2004-05-07 2005-05-06 Verfahren zur diagnose oder behandlung von prostatakrebs mittels erg-gen, alleine oder in kombination mit anderen ober- oder unterexprimierten genen bei prostatakrebs
EP05779973.6A Active EP1747292B1 (de) 2004-05-07 2005-05-06 Verfahren zur diagnose oder behandlung von prostatakrebs mittels erg-gen, alleine oder in kombination mit anderen ober- oder unterexprimierten genen bei prostatakrebs

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP05779973.6A Active EP1747292B1 (de) 2004-05-07 2005-05-06 Verfahren zur diagnose oder behandlung von prostatakrebs mittels erg-gen, alleine oder in kombination mit anderen ober- oder unterexprimierten genen bei prostatakrebs

Country Status (7)

Country Link
US (9) US10066268B2 (de)
EP (2) EP2383350B1 (de)
JP (1) JP5009787B2 (de)
AU (1) AU2005245815B2 (de)
CA (2) CA2992180C (de)
IL (1) IL179059A0 (de)
WO (1) WO2005113816A2 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090226915A1 (en) * 2001-01-24 2009-09-10 Health Discovery Corporation Methods for Screening, Predicting and Monitoring Prostate Cancer
US20090215024A1 (en) * 2001-01-24 2009-08-27 Health Discovery Corporation Biomarkers upregulated in prostate cancer
US20090215058A1 (en) * 2001-01-24 2009-08-27 Health Discovery Corporation Methods for screening, predicting and monitoring prostate cancer
ES2550614T3 (es) 2004-04-09 2015-11-11 Genomic Health, Inc. Marcadores de expresión génica para predecir la respuesta a la quimioterapia
EP2383350B1 (de) * 2004-05-07 2018-07-11 Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Verfahren zur diagnose oder behandlung von prostatakrebs mittels erg-gen, alleine oder in kombination mit anderen ober- oder unterexprimierten genen bei prostatakrebs
US11105808B2 (en) 2004-11-12 2021-08-31 Health Discovery Corporation Methods for screening, predicting and monitoring prostate cancer
US9957569B2 (en) * 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
WO2007033187A2 (en) 2005-09-12 2007-03-22 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
WO2008018625A2 (en) 2006-08-09 2008-02-14 Oncotherapy Science, Inc. Prostate cancer related gene styk1
FI20060751A0 (fi) * 2006-08-23 2006-08-23 Valtion Teknillinen Menetelmä prostatasyövän hoitoon ja mainitusta menetelmästä hyödyntävien potilaiden seulonta
EP1900824A1 (de) * 2006-09-14 2008-03-19 Deutsches Krebsforschungszentrum Stiftung Des Öffentlichen Rechts Genexpressionsprofile zur Prognose, Diagnose und Therapie von Prostatakrebs und deren Verwendung
AU2016222467B2 (en) * 2006-10-10 2017-11-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Prostate cancer-specific alterations in ERG gene expression and detection and treatment methods based on those alterations
EP2518163B1 (de) 2006-10-10 2014-08-06 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Prostatakrebs-spezifische Änderungen bei der ERG-Genexpression sowie auf diesen Änderungen basierende Nachweisverfahren
AU2014200037B2 (en) * 2006-10-10 2016-06-02 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Prostate cancer-specific alterations in ERG gene expression and detection and treatment methods based on those alterations
CA2687787A1 (en) * 2007-05-21 2008-12-18 Dana Farber Cancer Institute, Inc. Compositions and methods for cancer gene discovery
JP5433572B2 (ja) 2007-07-06 2014-03-05 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ｍｉｐｏｌ１−ｅｔｖ１遺伝子再編成
WO2009012387A2 (en) * 2007-07-18 2009-01-22 Gen-Probe Incorporated Compositions and methods to detect tmprss2/erg transcript variants in prostate cancer
US8106037B2 (en) 2007-08-03 2012-01-31 The Brigham And Women's Hospital, Inc. Identification and treatment of estrogen responsive prostate tumors
AU2008354371B2 (en) * 2008-04-10 2015-07-09 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Prostate cancer-specific alterations in ERG gene expression and detection and treatment methods based on those alterations
JP5925116B2 (ja) * 2009-04-29 2016-05-25 ザ・ヘンリー・エム・ジャクソン・ファンデイション・フォー・ジ・アドヴァンスメント・オヴ・ミリタリー・メディシン、インコーポレイテッド Ｅｒｇモノクローナル抗体
CA2763608C (en) 2009-05-26 2020-12-29 Quest Diagnostics Investments Incorporated Methods for detecting gene dysregulations
WO2011034906A2 (en) 2009-09-17 2011-03-24 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
WO2011037936A2 (en) * 2009-09-24 2011-03-31 Oregon Health & Science University Detection of dna methylation of tal1, erg and/or cd40 to diagnose prostate cancer
WO2011079191A1 (en) 2009-12-23 2011-06-30 Quest Diagnostics Investments Incorporated Tmprss2 for the diagnosis of prostate disease
MX338883B (es) 2010-07-27 2016-05-04 Genomic Health Inc Metodo para usar expresion de gen para determinar el pronostico de cancer de prostata.
US8945556B2 (en) 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions
JP2012231786A (ja) * 2011-04-18 2012-11-29 Kyushu Univ 標的遺伝子の発現変化による食品機能成分及び医薬品感受性評価方法
EP2742123B1 (de) * 2011-08-08 2017-11-08 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Isolierung und nachweis von krebszellen
EP3492606B1 (de) * 2011-08-22 2023-10-04 Exosome Diagnostics, Inc. Urinbiomarker
WO2013033073A1 (en) * 2011-08-31 2013-03-07 Ventana Medical Systems, Inc. Expression of ets related gene (erg) and phosphatase and tensin homolog (pten) correlates with prostate cancer capsular penetration
JP6351112B2 (ja) 2012-01-31 2018-07-04 ジェノミック ヘルス， インコーポレイテッド 前立腺癌の予後を定量化するための遺伝子発現プロフィールアルゴリズムおよび試験
CN102657878B (zh) * 2012-05-01 2014-04-16 浙江大学 Ints6基因小激活rna在制备抗前列腺癌药物中的应用
WO2014012176A1 (en) * 2012-07-20 2014-01-23 Diagnocure Inc. Methods, kits and compositions for providing a clinical assessment of prostate cancer
EP2882869A4 (de) * 2012-08-07 2016-04-20 Jackson H M Found Military Med Prostatakrebs-genexpressionsprofile
EP2971177B1 (de) * 2013-03-14 2019-09-11 Neogenomics Laboratories, Inc. Zusammensetzungen und verfahren zur erkennung und bestimmung einer prognose für prostatakrebs
JP2017509351A (ja) * 2013-12-30 2017-04-06 ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド 前立腺癌遺伝子プロファイル及びその使用方法
US9994912B2 (en) 2014-07-03 2018-06-12 Abbott Molecular Inc. Materials and methods for assessing progression of prostate cancer
DE102014110923B4 (de) * 2014-07-31 2016-06-02 Schott Ag Geformter Glas- oder Glaskeramikartikel
WO2017079618A1 (en) * 2015-11-06 2017-05-11 Miraca Life Sciences, Inc. Methods for determining high-grade prostatic intraepithelial neoplasia risk stratification
JP7046007B2 (ja) 2016-05-26 2022-04-01 ベクトン・ディキンソン・アンド・カンパニー 分子標識カウントの調節方法
US11164659B2 (en) * 2016-11-08 2021-11-02 Becton, Dickinson And Company Methods for expression profile classification
SG11201903158RA (en) 2016-11-08 2019-05-30 Cellular Res Inc Methods for cell label classification
US20220260507A1 (en) * 2019-07-17 2022-08-18 Prosight Ltd. Method and system for analyzing prostate biopsy

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197563B1 (en) 1985-03-28 2001-03-06 Roche Molecular Systems, Inc. Kits for amplifying and detecting nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5283174A (en) 1987-09-21 1994-02-01 Gen-Probe, Incorporated Homogenous protection assay
JP2650159B2 (ja) 1988-02-24 1997-09-03 アクゾ・ノベル・エヌ・ベー 核酸増幅方法
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5480784A (en) 1989-07-11 1996-01-02 Gen-Probe Incorporated Nucleic acid sequence amplification methods
CA2020958C (en) 1989-07-11 2005-01-11 Daniel L. Kacian Nucleic acid sequence amplification methods
US5427930A (en) 1990-01-26 1995-06-27 Abbott Laboratories Amplification of target nucleic acids using gap filling ligase chain reaction
CA2092323A1 (en) 1990-10-01 1992-04-02 George Y. Wu Targeting viruses and cells for selective internalization by cells
US5455166A (en) 1991-01-31 1995-10-03 Becton, Dickinson And Company Strand displacement amplification
ATE199647T1 (de) 1991-05-14 2001-03-15 Univ Connecticut Gerichtete abgabe von genen, die immunogene proteine kodieren
AU2160992A (en) 1991-06-05 1993-01-12 Board Of Regents Acting For And On Behalf Of The University Of Michigan, The Targeted delivery of genes encoding secretory proteins
WO1993014188A1 (en) 1992-01-17 1993-07-22 The Regents Of The University Of Michigan Targeted virus
CA2133411A1 (en) 1992-04-03 1993-10-14 Alexander T. YOUNG Gene therapy using targeted viral vectors
WO1993024656A1 (en) 1992-05-29 1993-12-09 Abbott Laboratories Ligase chain reaction starting with rna sequences
ATE200625T1 (de) 1992-10-09 2001-05-15 Advanced Tissue Sciences Inc Leberreservezellen
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US5861242A (en) 1993-06-25 1999-01-19 Affymetrix, Inc. Array of nucleic acid probes on biological chips for diagnosis of HIV and methods of using the same
US5925517A (en) 1993-11-12 1999-07-20 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide probes, assays and kits
AU687535B2 (en) 1994-03-16 1998-02-26 Gen-Probe Incorporated Isothermal strand displacement nucleic acid amplification
DE69840669D1 (de) 1997-04-10 2009-04-30 Stichting Katholieke Univ Pca3, pca3-gene und verfahren zu ihrer verwendung
CA2333253C (en) 1998-07-02 2010-09-07 Gen-Probe Incorporated Molecular torches
US20010010934A1 (en) * 1998-07-31 2001-08-02 Towia Aron Libermann Prostate derived ets factor
US6277628B1 (en) * 1998-10-02 2001-08-21 Incyte Genomics, Inc. Linear microarrays
ES2393056T3 (es) 1998-11-09 2012-12-18 Eiken Kagaku Kabushiki Kaisha Procedimiento de síntesis de ácido nucleico
WO2001038585A2 (en) * 1999-11-24 2001-05-31 The Regents Of The University Of California Polymer arrays and methods of using labeled probe molecules to identify and quantify target molecule expression
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
WO2001088122A2 (en) 2000-05-16 2001-11-22 Glaxo Group Limited Erg modulators
AU2001261676A1 (en) 2000-05-16 2001-11-26 Glaxo Group Limited Method and reagent for the inhibition of erg
FR2817043A1 (fr) 2000-11-17 2002-05-24 Univ Paris Curie Utilisation de l'il-18 comme facteur de pronostic du cancer de la prostate
JP3551311B2 (ja) 2001-01-31 2004-08-04 株式会社オービックビジネスコンサルタント 仕訳入力支援機能付会計処理システム
JP2002360255A (ja) 2001-05-31 2002-12-17 Univ Hospital Nijmegen ＰＣＡ３ｄｄ３、新規前立腺抗原のためのプロモーターを含む核酸分子、及びその使用
US20030108963A1 (en) * 2001-07-25 2003-06-12 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kit, and methods for identification, assessment, prevention and therapy of prostate cancer
AU2002335640A1 (en) * 2001-08-17 2003-03-03 Affymetrix, Inc. Gleason grade 4/5 prostate cancer genes
US20030148519A1 (en) 2001-11-14 2003-08-07 Engelke David R. Intracellular expression and delivery of siRNAs in mammalian cells
US6949342B2 (en) 2001-12-21 2005-09-27 Whitehead Institute For Biomedical Research Prostate cancer diagnosis and outcome prediction by expression analysis
TW200418988A (en) * 2002-09-30 2004-10-01 Oncotherapy Science Inc Method for diagnosing prostate cancer
WO2004076614A2 (de) * 2003-02-27 2004-09-10 Bernd Hinzmann Humane nukleinsäuresequenzen aus prostatakarzinomen
WO2004076814A1 (en) 2003-02-28 2004-09-10 Schlumberger Canada Limited Wireline telemetry data rate prediction
US20040181821A1 (en) 2003-03-14 2004-09-16 Jiadong Zhou siRNA research tool kit
WO2005007830A2 (en) 2003-07-14 2005-01-27 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
EP2383350B1 (de) 2004-05-07 2018-07-11 Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Verfahren zur diagnose oder behandlung von prostatakrebs mittels erg-gen, alleine oder in kombination mit anderen ober- oder unterexprimierten genen bei prostatakrebs
CN102680686A (zh) 2004-08-13 2012-09-19 千年药品公司 用于鉴定、评估、预防和治疗前列腺癌的基因、组合物、试剂盒和方法
JP5925116B2 (ja) 2009-04-29 2016-05-25 ザ・ヘンリー・エム・ジャクソン・ファンデイション・フォー・ジ・アドヴァンスメント・オヴ・ミリタリー・メディシン、インコーポレイテッド Ｅｒｇモノクローナル抗体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
AU2005245815B2 (en) 2011-06-09
US20120295282A1 (en) 2012-11-22
US20170198352A1 (en) 2017-07-13
US9347101B2 (en) 2016-05-24
EP1747292B1 (de) 2015-07-08
WO2005113816A3 (en) 2007-08-09
CA2565450C (en) 2018-03-06
US20150045240A1 (en) 2015-02-12
US9464325B2 (en) 2016-10-11
EP1747292A2 (de) 2007-01-31
US20180258497A1 (en) 2018-09-13
US10066268B2 (en) 2018-09-04
AU2005245815A1 (en) 2005-12-01
US20130029860A1 (en) 2013-01-31
CA2992180C (en) 2021-02-23
CA2992180A1 (en) 2005-12-01
JP5009787B2 (ja) 2012-08-22
US20130281674A1 (en) 2013-10-24
US20090170075A1 (en) 2009-07-02
US20170081729A1 (en) 2017-03-23
JP2007535939A (ja) 2007-12-13
IL179059A0 (en) 2007-03-08
US11236395B2 (en) 2022-02-01
WO2005113816A2 (en) 2005-12-01
EP2383350A1 (de) 2011-11-02
US9868993B2 (en) 2018-01-16
US20160376378A1 (en) 2016-12-29
CA2565450A1 (en) 2005-12-01

Similar Documents

Publication Publication Date Title
US11236395B2 (en) Methods of diagnosing or treating prostate cancer using the ERG gene, alone or in combination with other over or under expressed genes in prostate cancer
US8044193B2 (en) Short interfering RNAs targeted to T-LAK cell-originated protein kinase (TOPK) polynucleotide
KR101828290B1 (ko) 자궁내막암 마커
US20160348178A1 (en) Disease-associated genetic variations and methods for obtaining and using same
WO2007112330A2 (en) Compositions and methods for detection, prognosis and treatment of colon cancer
US20110224313A1 (en) Compositions and methods for classifying lung cancer and prognosing lung cancer survival
WO2005070020A2 (en) Gefitinib sensitivity-related gene expression and products and methods related thereto
CN108949969B (zh) 长链非编码rna在结直肠癌中的应用
WO2010030857A2 (en) Egfr inhibitor therapy responsiveness
EP1612281A2 (de) Verfahren zur Beurteilung von Patienten mit akuter myeloischer Leukämie
AU2011213720B2 (en) Methods of diagnosing or treating prostate cancer using the ERG gene, alone or in combination with other over or under expressed genes in prostate cancer

Legal Events

Date Code Title Description
AC Divisional application: reference to earlier application

Ref document number: 1747292

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120430

17Q First examination report despatched

Effective date: 20140312

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20180122

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF

AC Divisional application: reference to earlier application

Ref document number: 1747292

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: CH

Ref legal event code: NV

Representative=s name: KIRKER AND CIE S.A., CH

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1016920

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180715

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602005054258

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1016920

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180711

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181011

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180711

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180711

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181111

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181012

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180711

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180711

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180711

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180711

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602005054258

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180711

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180711

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180711

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180711

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180711

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180711

26N No opposition filed

Effective date: 20190412

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180711

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180711

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20190531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190506

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180711

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190506

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181111

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180711

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20050506

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230519

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20240526

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240527

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240530

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20240602

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240527

Year of fee payment: 20